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INTRODUCTION  
 
AGING, HEALTHY AGING AND LONGEVITY  
 
Life expectancy rose dramatically in the last century.  
The life expectancy at birth, also known as the average lifespan, represents the mean number of 
years lived by a cohort of individuals and Western world allows ever larger proportions of the 
population to reach an age that is far beyond that of the reproductive phase (1). Medicine and 
Health sciences have ameliorate global health both from important drugs discoveries, first of all 
antibiotics, and from interventions to public health such as massive vaccinations. 
Human life expectancy causes can be dived in two categories:  
? Reduction of the infant, childhood and young adult mortality, mostly due the public health 
interventions and antibiotics and vaccines that reduce deaths from infectious diseases  
? Reduction in old ages mortality, mostly due to prevention and pharmaceutical or procedural 
interventions for cardiovascular disease and cancer. 
The improvements of the social-environmental conditions, and medical cares and the quality of life 
caused a general improvement of the health status of the population, with a consequent reduction of 
the overall morbidity and mortality, resulting in an increase of life expectancy. After the 
demographic phenomena of the 19th century, characterized by an increase of the world population, 
we are now in the middle of a second demographic revolution, represented by the increase in the 
number of elderly people. Moreover, the improvement in public health has reduced the principal 
causes of mortality in the elderly, allowing an increasing number of individuals to reach the 
maximum lifespan age that represents the age of the longest lived member(s) of the population. 
Indeed, around the 1950s, in all industrialized countries, the progressive decline of mortality (1–2% 
per year) in individuals over 80 years old has increased, so that the number of centenarians has 
augmented about 20 times (2-3). 
In Italy, life expectancy is 76,8 years for men and 82,9 years for women (4). According to the U.S. 
Consensus bureau data, life expectancy in Italy is to increase, while birth rates will remain the 
same, producing an increasing to the old and very old population (5). (Figure 1)  
The progressive increase of oldest old people has brought to a new condition, i.e. the increase of 
different age groups such as octogenarians, nonagenarians and centenarians. This situation leads to 
extremely complicated demographic phenomena together with new problems regarding the 
allocation of resources for old age pensions and care for the elderly. 
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Figure 1: The age Pyramid in Italy in 2010 and 2035 
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AGING AND HEALTHY AGING 
Until some decades ago, it was believed that all the physiological functions of the organism 
underwent a simultaneous age-related decline (6). Other authors tried to quantify such a decline on 
the basis of cross-sectional comparison of data obtained from groups of subjects of different age 
belonging to different cohorts, who showed a decrease of about 1% per year for most of the 
physiological functions, and these data were considered valid for the great majority of the organs of 
the body. Such a decrease would be detectable from 30 years of age onwards according to some 
authors (7), whilst for some others, it would become evident even earlier, since the age of sexual 
maturation (8). Longitudinal studies suggested that the most striking age-related changes occur after 
the age of seventy (9). An updated vision of the phenomenon proposes that human ageing should be 
considered as a dynamic process leading to a continuous adaptation of the body to the life-long 
exposure to harmful stresses. This vision has been conceptualised in the so-called “remodelling 
theory of ageing” (10-11), which is mostly based on evidences obtained from studies on 
immunosenescence. In particular, these results show that immune functions are differently affected 
by ageing, being some parameter strongly affected whereas some other remain unchanged or even 
increased (12-14). The same can be observed in centenarians in good health conditions, who have 
some types of immune response well preserved (15-20). 
Of great interest to gerontologists is that a subset of the exceptionally aged does seem to delay or 
avoid major clinical diseases and disability into their 90s or 100s (21-23). These subjects are the 
best example of extreme longevity in our species, and they represent a selected population in which 
the appearance of major age-related diseases, such as cancer, and cardiovascular diseases among 
others, has been consistently delayed or escaped (24-26). 
 
Immunosenescence and inflamm-ageing 
A decreased ability to maintain homeostasis in response to external stressful stimuli, e.g. physical 
stress, starvation, can be demonstrated in the elderly. This deficit decreases the ability to maintain 
homeostasis, with an increased occurrence of diseases and death (27). In Western countries, the 
mortality of individuals over 60 years old is up to 25 times that of people 25–44 years old by the 
following factors: 92-fold for heart disease, 43-fold for cancer, 100-fold for stroke, 100-fold for 
chronic lung disease, and 89-fold for pneumonia and influenza (28). These data suggest a key role 
for clonotypic and innate immunity in the control of the survival of the elderly, because resistance 
to these diseases depends, at least in part, on a well-functioning immune system (29). 
The ageing of the immune system, immunosenescence, is the consequence of the continuous 
attrition caused by chronic antigenic overload. Some of the most important characteristics of 
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clonotypic immunity in ageing are compatible with this assumption since it is characterized by a 
decrease of virgin T cells and by the filling up of the immunological space by “megaclones” of 
memory T cells, resistant to apoptosis and capable of exerting negative regulatory functions (30-
33). Concomitantly, the antigenic load results in the progressive generation of inflammatory 
responses involved in age-related diseases, for which the name “inflamm-ageing” has been 
proposed (27). Most of the parameters influencing immunosenescence appear to be under genetic 
control, and research is trying to address this point (29, 34). Therefore, immunosenescence fits the 
basic assumptions of evolutionary theories of ageing, such as antagonistic pleiotropy. In fact, the 
immune system, by neutralizing infectious agents, plays a beneficial role until the time of 
reproduction and parenting. Subsequently, determining a chronic inflammation can play a 
detrimental role late in life, a period largely unforeseen by evolution (35). 
Thus, immunological features such as a powerful innate immunity and a high capacity to mount a 
strong inflammatory response, useful to survive infections at younger age in the past centuries and 
millennia, can become detrimental later in life in economically developed countries which allow 
people to survive for several decades after the age of reproduction. Inflamm-ageing can thus be 
considered the main driving force for major age-related diseases and the evolutionary price to pay 
for an immune system fully capable of defending against infectious diseases at younger, 
reproductive age (34, 36-39). These major features of immunosenescence fit the data collected in 
the framework of the Italian centenarians, as discussed by Sansoni et al. (40). 
Besides the pro-inflammatory status, these subjects are characterized by a state of hyper-
coagulability. This last point suggest that high plasma levels of the coagulation activation markers 
in older population do not necessarily mirror a higher risk of arterial or venous thrombosis and it is 
compatible with the attainment of extreme ages, as described by Mari et al. (41). 
Metabolic features 
Data collected within the Italian centenarians also suggest that age-related changes in metabolic 
pathways and endocrine functions may occur. The findings on the higher frequency of the 
apolipoprotein-E (APOE) ε4 allele in middle-aged subjects than in centenarians were substantially 
confirmed (42). On the contrary, Italian findings did not confirm previous data on increased 
prevalence of the high-risk angiotensin I converting enzyme 1 (ACE1) D allele in French 
centenarians. The variability in the strength of association between ACE1 polymorphism and 
longevity could be related to regional differences in ACE1*D frequency in Europe, as recently 
reported for apoE ε2 and ε4 allele in centenarians (43). 
Moreover, centenarians appear to have a remarkably low level of insulin resistance and favourable 
marker of glucose metabolism as discussed by Barbieri et al. (44). Accordingly, the phenomenon of 
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insulin resistance shows an age-related increase, and it reaches the highest peak in the cohort of 80- 
to 90-year-old people, but there is a significant reduction of insulin resistance in subjects of 90 and 
100 years. The major finding of such studies was that age-related insulin resistance is not an 
obligatory finding in the elderly. Why oldest old subjects have a lower degree of insulin resistance 
compared to aged (age>65 years) subjects, is unknown. The lack of insulin resistance in healthy 
centenarians should be considered as the living evidence that a successful metabolic age-dependent 
remodelling might provide a consistent contribution for the extreme life span in this special group 
of subjects. 
On the other hand, it results that a severe D hypovitaminosis plays an important role in the oldest 
old as a factor inducing a vicious circle involving hypocalcaemia, secondary hyperparathyroidism, 
even in the presence of sufficient renal functions, accompanied by a biochemical situation 
indicating a consistent loss of bone mass as discussed by Passeri et al. (45). 
Furthermore, to better understand the effect of some neuroendocrine changes in ageing process, the 
adrenocortical, pineal and thyroid secretion in old and very old healthy subjects was studied by 
Ferrari et al. (46). Their findings suggest the maintenance of a certain circadian organization of 
melatonin secretion in centenarians and this could be considered as a marker of successful ageing. 
 
Presence of diseases 
From a clinical point of view, centenarians appear to be characterized by a large heterogeneity. 
Indeed their clinical status may vary from people in quite good shape from a physical and a 
cognitive point of view to subjects in bad shape affected by physical disability and dementia. Two 
pathologies appear to have a higher frequency in centenarians than in the elderly, i.e. cognitive 
impairment and respiratory pathologies. The former is about the 82.6% in all the centenarians (but, 
as pointed out, the tests used to assess cognitive ability have not been validated); the latter strike a 
percentage of centenarians double with respect to the elderly, basing on autoptic data on 
broncopneumonias and chronic obstructive pulmonary disease; moreover clinical data indicate that, 
apart cough and catarrh, respiratory pathologies are present in 26.2% of centenarians (IMUSCE 
unpublished observations). 
Among centenarians, smoking is extremely rare, and even when it occurs among them, it is 
correlated almost exclusively to bad health conditions and non-autosufficiency, indicating that it 
compromises health status and the quality of life even in extremely long-living subjects (47). 
Moreover, it appears that diseases as Parkinson disease, diabetes, thyreopathies are less frequent in 
centenarians than in elderly people. In particular, it is interesting to note that diabetes occurs in the 
oldest old population with a lower frequency than in the normal elderly, and becomes clinically 
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apparent usually only after 90 years of age. Diabetes in the oldest old persons is paucisymptomatic, 
and neodiagnosed diabetes is most frequently found in centenarians. The long-lasting diabetes, 
which starts at an age of about 60 years or earlier, usually does not allow attaining 100 years of age. 
Another major killer in old age is represented by cardiovascular diseases. It would be expected that 
centenarians are protected from this type of pathologies (25,26) and indeed the data on 140 
autopsies in centenarians compared with the same number of autopsies in elderly subjects suggest 
that, while ischemic cardiopathies and cerebrovascular pathologies are similar in the two groups, 
acute myocardial infarction and cardiac amyloidosis are much less and much more frequent in 
centenarians than in elderly people, respectively.  
 
In conclusion, the best definition for the healthy aging in very old subjects could be “good healthy 
status for their age”. It combines the awareness that centenarians are de facto extremely old, and 
shows the sign of ageing, but at the same time clearly indicates that they are in good shape 
notwithstanding their very advanced age, on the basis of standardized criteria regarding the 
cognitive and physical abilities. With all these methodological limitations in mind, these data 
suggest that “healthy ageing” is a real possibility for human beings and cast some doubt on the 
pessimistic view that extreme age must always be accompanied with severe diseases and/or 
disabilities(48). 
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LONGEVITY  
Human longevity is a complex trait resulting from the interaction among environment, genetics and 
stochasticity, (49,50) which has specific and unusual characteristics (38, 51, 52). Human longevity 
does not appear to be homogenously distributed from a geographical point of view, (53-55) and it 
seems to be clustered in families enriched in long-lived parents and ancestors (56). Human studies 
of longevity face numerous theoretical and logistical challenges, as the determinants of life span are 
extraordinarily complex (57). Longevity can be achieved by different combinations of genetics, 
environment and chance, that vary, quantitatively and qualitatively, in different geographic areas 
according to the population-specific gene pool and to the socioeconomic level of the population. 
(51) 
However, large-scale linkage studies of long-lived families, longitudinal candidate-gene association 
studies and the development of analytical methods provide the potential for future progress, 
assuming that both public and private genetic variants contribute to such a very complex trait as the 
healthy aging and longevity in humans (57). 
 
Extreme longevity could be considered as a new phase of life which is characterized by two types 
of remodelling: 
a) immunological remodelling (immunosenescence). 
During aging the immune system progressively changes in a dynamic process 
(immunosenescence) which mainly depends on the evolutionary unpredicted, chronic antigenic 
load persisting lifelong. This leads to the development of a chronic, low grade inflammatory 
procees (inflammaging) (27), which however is compatible with 100 years of age, because 
centenarians have also high levels of anti-inflammatory markers and protective genotypes of 
important molecules. 
 
b)  genetic remodelling (post-reproductive genetics).  
A complex genetic remodelling also occurs with age (post-reproductive genetics), whose main 
characteristics indicate that: the same alleles likely have different (beneficial or detrimental 
effect at different ages  (genes involved in IGF-1/Insulin pathway (58)), protective genes 
become progressively more important with age (like Il-10). 
 
Recent studies on the genetic of human longevity have suggest that: 
1) human longevity clusters in families; 
2) long-living siblings are likely enriched in longevity genes. 
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Actually, an impressive and coherent series of epidemiological data from different populations 
(White Americans from New England, Mormons from Utah, Ashkenazi Jewish living in the United 
States, Icelanders, Japanese from Okinawa, Netherlanders from Leiden, Danish collected in the 
entire nation, Italians from Southern Italy) suggests the presence of a strong FAMILIAR component 
of human longevity. All these studies demonstrate that first-degree relatives (parents, siblings, and 
offspring) of long-lived subjects (but not the spouses of the long-lived subjects who shared with 
them most part of their adult life) have a significant survival advantage, a higher probability to have 
been or to become long-living people and to have a lower risk regarding the most important age-
related diseases, such as cardio- and cerebrovascular diseases (CVD), diabetes, and cancer, when 
compared to appropriate controls.(25-26, 59-61). Thus, literature indicates that longevity is present 
in many generations of a single family in spite of the great variations in lifestyle and life expectancy 
as it occurred in the last century. In particular, it is remarkable that in the most recent studies on this 
topic, spouses of long-lived subjects were added as additional control group. The results indicate 
that this control group does not have any advantage/benefit in terms of survival and protection from 
the above-mentioned diseases, even if they shared with the long-lived partner most of their adult 
life. 
In particular, as far as parents, siblings, and offspring of centenarians are concerned, the available 
data indicate that: 
(1) CENTENARIANS have the following characteristics: 
? A lower prevalence of cancer, CVD, insulin-resistance and diabetes, and a delay of about 
1–2 decades of the onset of others pathologies, such as dementia and hip fractures (62). 
? Most of them do not show insulin-resistance and have anthropometric (BMI), metabolic 
(cholesterol, LDL-C, HDL-C, triglycerides, etc.), and cardiovascular (systolic and 
diastolic pressure) features that are optimal for their age (63). 
? Their successful aging seems to be largely influenced by their optimal balance between 
inflamm-aging and anti-inflammaging (52). Centenarians appear to have the capability to 
set up responses capable of neutralizing or at least diminishing the deleterious effect of the 
low-grade, chronic inflammatory status, characteristics of the aging process (inflamm-
aging), which in turn is largely a consequence of the level of subclinical antigenic 
stimulation sustained by bacteria, viruses, and other pathogens. 
? The above-mentioned characteristics can explain the finding in centenarians of a different 
frequency of a variety of polymorphisms of genes involved in immune response, 
inflammation, coagulation, and lipid and glucose metabolism, in comparison with younger 
controls (association studies) (58, 64-72). However, most of these studies need to be 
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replicated in different populations and contrasting data have been obtained in different 
studies. 
? A different frequency of germ line variants of mtDNA (73). 
To this regard it is important to remind that it is still unclear whether and how much the different 
populations of long-lived individuals (centenarians and nonagenarians) studied so far (Ashkenazi 
Jewish, Danish, French, Finnish, German, Irish, Islandic, Italians, Japanese, Mormons, among 
others) share the same genetic markers of longevity and whether “public” and/or “private” 
(population specific) longevity genes and polymorphisms do exist in different populations and/or 
individuals. 
 
(2) PARENTS OF CENTENARIANS have a higher “risk” (about 7 times) to reach extreme longevity 
(90–99 years old) (59). Parents' longevity is probably important and interesting from a biomedical 
point of view, as demonstrated by two recent studies: 
? According to an investigation performed on 1402 members of 288 pedigrees within the 
framework of the Framingham Heart Study, genetic factors explained an additional 57% of 
biological age variability (60) 
? According to a study performed in 51,485 men and women aged 40–79 years, the risk of 
mortality from all death causes including stroke and CVD was 20–30% lower in men and 
women with parents who died at age equal or higher than 80 years (fathers) and equal or 
higher than 85 years (mothers), compared with subjects having parents whose age at death 
was lower than 60 years (fathers) and lower than 65 years (mothers). These findings indicate 
that parental longevity could be a predictor for reduced risk of mortality from stroke, CVD, 
and all causes of death (61). 
 
(3) SIBLINGS OF CENTENARIANS also have an advantage for survival and for attaining extreme 
longevity: 
? In a study on 2092 centenarian siblings, it has been demonstrated that both males and 
females have a mortality 50% lower than that of 1900 subjects of the same birth cohort, and 
their relative survival probabilities increase markedly at older ages, reflecting the cumulative 
effect of their mortality advantage throughout life. Male siblings of centenarians were at 
least 17 times as likely to attain the age of 100 years, while female siblings were at least 8 
times as likely (74). 
? From the analysis of the pedigrees of 348 Okinawan centenarian families with 1142 siblings 
it resulted that both male and female centenarian siblings experienced approximately half 
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mortality of their birth cohort-matched counterparts of the general Okinawan population 
(55). Remarkably, this mortality advantage of centenarians siblings was sustained at all ages 
and decades, and did not diminish or disappear with age in contrast to many 
environmentally based mortality gradients (gender, ethnicity, nutritional factors, such as 
cholesterol, physical activity, economical status, education level), suggesting that the 
familiar component is mostly genetically related. 
? In families with at least two long-living siblings (men aged 89 years or more and women 
aged 91 years or more), the rest of their siblings, their parents, and their offspring, but not 
their spouses (husbands and wives), showed a major survival and a mortality rate for all 
causes of death that was 35% less than in the general population (75). 
 
Schoenmaker et al. (75) studied families with at least two long-living siblings (men: 89 years and 
over; women: 91 years and over) and showed that the standardized mortality ratio for all siblings of 
the long-living participants was 0.66 and that a similar survival benefit was also observed in the 
parents (0.76) and in the offsring (0.65) of the long-living participants. The standardized mortality 
ratios of the spouses of the long-living subjects was 0.95. The authors conclude that: (a) it is 
unlikely that the familiar clustering of extended survival is caused by environmental factors, 
because the spouses of the long-living participants had a mortality risk comparable with the general 
Dutch population, whereas they share the same environment; and (b) families with two long-living 
siblings are genetically enriched for extreme survival. 
 
Hjelmborg et al.(76) start from the consideration that although human familiy studies have 
indicated that a modest amount of the overall variation in adult life span (approximately 20–30%) is 
accounted for by genetic factors, it is not known if they become increasingly important for survival 
at the oldest ages. The genetic influence on human life span and how it varies with age was studied 
in cohorts of Danish and Finnish twins born between 1870 and 1910 (20,502 indiduals) followed 
until 2003–2004. Mean life span for male monozygotic (MZ) twins increases 0.39 years for every 
year his cotwin survives over age 60 years, and this rate is higher than the rate of 0.21 for dizygotic 
(DZ) males. Females and males have similar rates and these are negligible before age 60 for both 
MZ and DZ pairs. Having a cotwin surviving to old ages substantially and significantly increases 
the chance of reaching the same old age and this chance is higher for MZ than for DZ twins. The 
authors conclude that: (a) such a large population-based study shows genetic influence on human 
life span; (b) this influence is minimal prior the age of 60 years but increases thereafter; and (c) 
these findings provide a support for the search for genes affecting longevity in humans, especially at 
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advanced ages; linkage studies in large samples of extremely long-lived siblings may be among the 
best approaches to identify such genes. 
 
(4) OFFSPRING OF CENTENARIANS presents a lower prevalence of CVD (56%), hypertension 
(66%), and diabetes (59%) and their median ages of onset for CVD, hypertension, diabetes, and 
stroke were significantly shifted forward by 5.0, 2.0, 8.5, and 8.5 years, respectively (58).  
? They had a 62% lower risk of all causes mortality, a 71% lower risk of cancer-specific 
mortality, and an 85% lower risk of coronary heart disease-specific mortality (59). 
? They had a favorable lipoprotein profile characterized by significantly larger HDL and LDL 
particle size and significantly increased homozygosity for the 405 valine allele (V allele) in 
the CETP gene (Cholesteryl Ester Transfer Protein) (77), and the −641 C allele in APOC3 
gene (60), similar to what has been observed in parents of centenarians. 
 
Christensen et al. (57) published a rich and comprehensive review which deliver several take home 
messages, including the followings: 
1. The determinants of life span are extraordinarily complex and human studies of longevity 
face theoretical and logistic challenges; 
2. Longevity clusters in some families but it is difficult to disentangle the effect of the shared 
environment and that of genetics; 
3. Owing to the complexity of the long-living phenotype, there is the possibility that different 
variants are involved in life-span variation in different populations; 
4. As the effect of the genetic component on longevity increases after the age of 60 years, 
nonagenarians and centenarians are particularly informative about longevity genes; 
5. Large sample size are needed to uncover alleles which occur only in a few percent of the 
population and that have a modest effect on survival; 
6. Large-scale and carefully designed study assessing long-lived siblings and controls, as well 
as studies on large cohorts of elderly people followed longitudinally, will be essential to 
progress in genetic studies of human longevity, especially if combined with high-throughput 
genotyping techniques; 
7. Genome-wide association studies are becoming feasible and are promising but logistically 
and financially demanding. 
 
On the whole, the above-mentioned data would suggest that the familiar component of longevity is 
fundamentally a GENETIC component. At the same time, they indicate that families enriched in 
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long-living members and, in particular, in very old siblings, and offspring of long-lived parents 
represent study groups particularly suitable to investigate the determinants of the human longevity. 
 
At present, it is still unknown how much this familiar component of longevity and successful 
ageing is due to genetics. This is a crucial issue from a theoretical (biology) and practical 
(biomedicine and public health) point of view, and the GEHA project is aimed to contribute to its 
clarification. 
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STROKE 
 
Symptoms of stroke include numbness, weakness or paralysis, slurred speech, blurred vision, confusion 
and severe headache (78). 
 
Stroke is defined by the World Health Organization (79) as a clinical syndrome consisting of 
‘rapidly developing clinical signs of focal (at times global) disturbance of cerebral function, lasting 
more than 24 h or leading to death with no apparent cause other than that of vascular origin’.  
 
Stroke is divided in Ischemic (80% of all stroke) and Hemorrhagic stroke.  
Ischemic stroke can be subdivided in major Ischemic stroke and in Transient Ischaemic Attack 
(TIA), while Hemorrhagic stroke can be caused by an Intracerebreral (15-20% of all strokes) or 
Subarachnoid (3% of all strokes) haemorrhage. 
 
A transient ischemic attack (TIA) is defined as stroke symptoms and signs that resolve within 24 
hours. However, there are limitations to these definitions. By conventional clinical definitions, the 
presence of focal neurological symptoms or signs lasting <24 hours has been defined as a TIA. With 
more widespread use of modern imaging techniques for the brain, up to one third of patients with 
symptoms lasting <24 hours have been found to have an infarction (80, 81). This has led to a new 
tissue-based definition of TIA: a transient episode of neurological dysfunction caused by focal 
brain, spinal cord, or retinal ischemia, without acute infarction (81). The distinction between TIA 
and ischemic stroke has become less important in recent years because many of the preventive 
approaches are applicable to both. TIA and ischemic stroke share pathophysiologic mechanisms, but 
prognosis may vary depending on severity and cause, and definitions are dependent on the timing 
and extent of the diagnostic evaluation.  
The true prevalence of TIA is difficult to measure because a large proportion of patients who 
experience a TIA fail to report it to a healthcare provider (82). A TIA is an important predictor of 
stroke. The 90-day risk of stroke after a TIA has been reported as being as high as 17%, with the 
greatest risk apparent in the first week.(83-84). 
 
The classification of ischemic stroke is based on the presumed mechanism of the focal brain injury 
and the type and localization of the vascular lesion. The classic categories have been defined as (85). 
? large-artery atherosclerotic infarction, (extracranial or intracranial);  
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? embolism from a cardiac source;  
? small-vessel disease;  
? other determined cause such as dissection; 
? hypercoagulable states; 
? sickle cell disease;  
? infarcts of undetermined cause.  
 
EPIDEMIOLOGY 
According to the WHO Global Burden of disease Project, Cerebrovascular disease represents the 2nd 
cause for global mortality and according the 2002 data was responsible for the death of 5.5 million 
people, representing the 9.7% of all deaths. 
The influence of Cerebrovascular Disease on global mortality is higher in the high-income countries 
were is the 3rd cause of burden of disease, measured in measured in disability-adjusted life-years 
(DALY), whereas in low and middle-income countries corresponds to the 6th cause of DALY (86). 
In Europe, the stroke incidence is similar in different regions even if it is slightly higher in the 
Northern area than in the Southern one (87).  
In Italy, according the Italian guidelines on stoke, stroke represents the 3rd cause of mortality  after 
the cardiovascular diseases and neoplasies, causing the 10-12% of all deaths/year and is the 
principal factor of invalidity . The prevalence of stroke in the elderly population (>65 y.o.) is of the 
6,5% (7,4% of males and 5,9% of females) (88).  
Stroke is also the leading cause of serious long-term disability. Studies using longitudinal data 
have determined the influence of older age and sex on disability after stroke (89-90), In the 
Framingham Study, women were found to be significantly older (75.1 vs 71.1) at the time of their 
initial stroke, more likely to be dependent in activities in daily living and mobility (91) and more 
than four times as likely than men to be institutionalized in a nursing home after stroke (92). 
The devastating residual disability associated with stroke, in addition to presence of other chronic 
illnesses at the time of the stroke, makes stroke one of the most feared consequences of aging. 
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STROKE IN THE ELDERLY 
The risk of stroke increases with age, the incidence doubling with each decade after the age of 45, 
and more than 70% of all strokes occur in people aged 65 and older. Of the estimated 795,000 new 
or recurring strokes that occur in the United States each year, approximately 145,000 will result in 
death (93). For the 6.5 million individuals who survive a stroke and are alive today, nearly half will 
have moderate to severe neurological deficits, 30% will be unable to walk unassisted, and more 
than 25% will need assistance in their daily activities.  
According Kelly-Hayes recent review on the influence of age on stroke risk, the overall lifetime risk 
for stroke (LTR) remaines relatively constant until 75 years of age, at 1 in 5 for women (20% to 
21%) and approximately 1 in 6 for men (14% to 17%). The LTR at 85 years of age is lower (16% 
for women and 10% for men; P<0.05 compared with participants 55 to 75 years of age). Although 
the incidence rate of stroke increased with age, this was counterbalanced by a decreasing residual 
life expectancy (Figure 2) (93). 
 
 
Figure 3. Sex-specific mortality-adjusted cumulative incidence of lifetime risk (LTR) of stroke.  
 
 
Similar results are reported in the Orlandi et al study (94) performed in an Italian rural population 
were as old age advances from 65 to 90 years and over, the prevalence of stroke increases a little 
more than twice in men and up to about fourfold in women, and at the oldest ages it tends to 
decrease in men whereas it reaches a plateau in women. An excess in mortality and case fatality, 
especially in males, likely accounts for this trend in the oldest subjects. Moreover, despite the 
overall prevalence values of 8.2% in males and 5.1% in females, the difference between sexes 
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decreases with age and becomes lower in men when compared to the women in the oldest range 
(figure 3). 
 
Figure 3. Stroke prevalence in Italy, 2001 
 
According the Italian Longitudinal Study on Aging (ILSA), an epidemiological study performed on 
5,632 individuals aged 65-84, has demonstrated that incidence for first-ever stroke was 9.51 (95% 
CI: 7.75-11.27) per 1,000 person years and 12.99 (95% CI: 10.99-14.98) including recurrent stroke 
(total incidence). Crude mortality resulted 49.2% among first stroke patients and 15% among 
persons without stroke. The first-ever stroke mortality risk ratio, adjusted for demographics and 
comorbidity, was 2.40 (95% CI: 1.62-3.54). The first-ever stroke mortality risk ratio, adjusted for 
demographics and comorbidity, was 2.40 (95% CI: 1.62-3.54). In survivors, impairment of at least 
one ADL was present in 67.6% of first-ever stroke patients vs. 31.6% of individuals without stroke. 
The comorbidity-adjusted OR was 2.63 (95% CI: 1.20-5.78) in the total cohort, and 4.00 (95% CI: 
1.39-11.46) in individuals without disability at baseline (95). 
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STROKE RISK FACTORS 
 
The American Heart Association and the American Stroke Association (96, 97) latest version of the 
for Primary Prevention of Stroke Guidelines, published in 2010, classifies the risk factors for stroke 
in  
• Nonmodifiable risk factors 
? Age 
? Sex 
? Low birth weight (<2500 g) 
? Race/ethnicity  
? Family history of stroke/TIA 
• Well-Documented and Modifiable Risk Factors 
? Hypertension 
? Cigarette smoking 
? Diabetes 
? Dyslipidemia 
? Atrial Fibrillation  
? Other Cardiac conditions (i.e. heart failure, valvular heart disease etc) 
? Asymptomatic Carotid Stenosis 
? Sickle Cell Disease 
? Postmenopausal Hormone Therapy 
? Oral Contraceptives 
? Diet and Nutrition  
? Physical Inactivity 
? Obesity and Body Fat Distribution 
• Less Well-Documented or Potentially Modifiable Risk Factors 
? Migraine 
? Alcohol Consumption 
? Sleep-Disordered Breathing 
? Drug abuse 
? Hyperhomocysteinemia 
? Hypercoagulability 
? Inflammation and Infection 
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Nonmodifiable Risk Factors 
 
Age 
Stroke is a disease of the elderly. Although younger age groups (25 to 44 years) are at lower stroke 
risk (102) the public health burden is high in these populations because of a relatively greater loss of 
productivity and wage-earning years. The cumulative effects of aging on the cardiovascular system 
and the progressive nature of stroke risk factors over a prolonged period substantially increase the 
risks of both ischemic stroke and intracerebral hemorrhage (ICH). The risk of ischemic stroke and 
ICH doubles for each successive decade after age 55. (97, 103-107) 
 
Sex 
Stroke is more prevalent in men than in women (97, 108). Men also generally have higher age-
specific stroke incidence rates than women have (based on age-specific rates calculated from strata 
defined by race/ethnicity), and this is true for ischemic as well as hemorrhagic stroke (97, 103, 107-
110) The exceptions are those 35 to 44 years of age and those >85 years of age (110,111).  
The earlier cardiac-related deaths (ie, competing causes of death) of men with cardiovascular 
disease (CVD) may contribute to the relatively greater risk of stroke in older women.  
 
Genetic Factors 
A meta-analysis of cohort studies showed that a positive family history of stroke increases risk of 
stroke by approximately 30% [odds ratio (OR), 1.3; 95% CI, 1.2 to 1.5, P<0.00001] (112). 
The odds of both monozygotic twins having strokes are 1.65-fold higher than those for dizygotic 
twins (112).  
Cardioembolic stroke appears to be the least heritable type of stroke compared with other ischemic 
stroke subtypes (113). Women with stroke are more likely than men to have a parental history of 
stroke (114). 
 
The increased risk of stroke imparted by a positive family history could be mediated through a 
variety of mechanisms, including: 
1. genetic heritability of stroke risk factors,  
2. inheritance of susceptibility to the effects of such risk factors,  
3. familial sharing of cultural/environmental and lifestyle factors, and  
4.  interaction between genetic and environmental factors.  
 
 19
Genetic influences on stroke risk can be considered on the basis of individual risk factors, genetics 
of common stroke types, and uncommon or rare familial stroke types. Many of the established and 
emerging risk factors described in the sections that follow, such as hypertension, diabetes, and 
hyperlipidemia, have both genetic and environmental/behavioral components (115-117). Elevations 
of blood homocysteine occur with 1 or more copies of the C677T allele of the 
methylenetetrahydrofolate reductase gene (118).  
Some apparently acquired coagulopathies, such as the presence of a lupus anticoagulant or 
anticardiolipin antibody, can be familial in approximately 10% of cases (125,126). Inherited 
disorders of various clotting factors (ie, factors V, VII, X, XI, and XIII) are autosomal recessive 
traits and can lead to cerebral hemorrhage in childhood or the neonatal period (119). Arterial 
dissections, moyamoya disease, and fibromuscular dysplasia have a familial component in 10% to 
20% of cases (127,128).  
Common variants on chromosome 9p21 adjacent to the tumor suppressor genes CDKN2A and 
CDKN2B, which were initially found to be associated with MI (129-131), have been found to be 
associated with ischemic stroke as well (132). Common variants on 4q25 adjacent to the PITX2 gene 
involved in cardiac development were first shown to be associated with atrial fibrillation (133). This 
locus was subsequently associated with ischemic stroke, particularly cardioembolic stroke (134).  
Several rare genetic disorders have been associated with stroke. Cerebral autosomal dominant 
arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is characterized by 
subcortical infarcts, dementia, and migraine headaches (135). CADASIL can be caused by any of a 
series of mutations in the Notch3 gene (135,136). Marfan syndrome (caused by mutations in the 
fibrillin gene) and neurofibromatosis types I and II are associated with an increased risk of ischemic 
stroke (137).  
Fabry disease is a rare inherited disorder that can also lead to ischemic stroke. It is caused by 
lysosomal -galactosidase A deficiency, which causes a progressive accumulation of 
globotriaosylceramide and related glycosphingolipids. Deposition affects mostly small vessels in the 
brain and other organs, although involvement of the larger vessels has been reported (138).  
Intracranial aneurysms tend to be more common within families (139-142).  
Intracranial aneurysms are a feature of certain Mendelian disorders, including autosomal dominant 
polycystic kidney disease (ADPKD) and Ehlers-Danlos type IV (EDS-IV) syndrome (so-called 
vascular Ehlers-Danlos). Intracranial aneurysms occur in about 8% of individuals with ADPKD and 
7% with cervical fibromuscular dysplasia (143,144). EDS-IV is associated with dissection of 
vertebral and carotid arteries, carotid-cavernous fistulae, and intracranial aneurysms (145).  
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Well-Documented and Modifiable Risk Factors 
 
Hypertension 
Hypertension is a major risk factor for both cerebral infarction and ICH. The relationship between 
blood pressure (BP) and stroke risk is strong, continuous, graded, consistent, independent, 
predictive, and etiologically significant (146). Throughout the usual range of BPs, including the 
nonhypertensive range, the higher the BP, the greater the risk of stroke (147). The risk of stroke 
increases progressively with increasing BP, and a substantial number of individuals have a BP level 
below the current drug treatment thresholds recommended in the Seventh Report of the Joint 
National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure  
 
Cigarette Smoking 
Virtually every multivariable assessment of stroke risk factors (eg, Framingham (148), 
Cardiovascular Health Study [CHS] (105), and the Honolulu Heart Study (149) has identified 
cigarette smoking as a potent risk factor for ischemic stroke. associated with an approximate 
doubling of risk for ischemic stroke (after adjustment for other risk factors). Data from studies 
largely conducted in older age groups also provide evidence of a dose-response relationship. 
Smoking is also associated with a 2- to 4-fold increased risk for subarachnoid hemorrhage (SAH) 
(150-153). The data for ICH, however, are inconsistent. A multicenter case-control study found an 
adjusted odds ratio of 1.58 (95% CI, 1.02 to 2.44) (154) for ICH and analyses from the Physicians' 
Health Study (153) and Women's Health Study (WHS) (152) also found such an association. But 
other individual studies, including a pooled analysis of the ARIC and CHS cohorts, found no 
relationship between smoking and risk of ICH (103,106,155,156). A meta-analysis of 32 studies 
estimated the relative risk for ischemic stroke to be 1.9 (95% CI, 1.7 to 2.2) for smokers versus 
nonsmokers; for SAH, 2.9 (95% CI, 2.5 to 3.5); and for ICH, 0.74 (95% CI, 0.56 to 0.98) (155). 
There is a definite relationship between smoking and both ischemic and hemorrhagic stroke, 
particularly at young ages (157,158). The annual number of stroke deaths attributed to smoking in 
the United States is estimated to be between 21 400 (without adjustment for potential confounding 
factors) and 17 800 (after adjustment), which suggests that smoking contributes to 12% to 14% of 
all stroke deaths (159).  
Cigarette smoking may also potentiate the effects of other stroke risk factors, including systolic BP 
(160), vital exhaustion (unusual fatigue, irritability, and feelings of demoralization) (161), and oral 
contraceptives (OCs) (162,163). The effect of cigarette smoking on ischemic stroke risk may be 
higher in young adults who carry the apolipoprotein E 4 allele. 
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Smoking likely contributes to increased stroke risk through both acute effects on the risk of 
thrombus generation in atherosclerotic arteries and chronic effects related to increased 
atherosclerosis (164). Smoking just 1 cigarette increases heart rate, mean BP, and cardiac index and 
decreases arterial distensibility (165,166). Beyond the immediate effects of smoking, both active 
and passive exposure to cigarette smoke is associated with the development of atherosclerosis (167). 
In addition to placing persons at increased risk for both thrombotic and embolic stroke, cigarette 
smoking approximately triples the risk of cryptogenic stroke among persons with a low 
atherosclerotic burden and no evidence of a cardiac source of emboli (168).  
 
Diabetes 
Persons with diabetes have both an increased susceptibility to atherosclerosis and an increased 
prevalence of proatherogenic risk factors, notably hypertension and abnormal blood lipids.  
Both case-control studies of stroke patients and prospective epidemiological studies have confirmed 
that diabetes independently increases risk of ischemic stroke with a relative risk ranging from 1.8-
fold to nearly 6-fold (169).  
In the Euro Heart Survey on Diabetes and the Heart, a total of 3488 patients were entered in the 
study: 59% without diabetes and 41% with diabetes (170). Evidenced-based medicine was defined 
as the combined use of renin-angiotensin-aldosterone system inhibitors, β-adrenergic receptor 
blockers, antiplatelet agents, and statins. In patients with diabetes, evidence-based medicine (RR, 
0.37; 95% CI, 0.20 to 0.67; P=0.001) had an independent protective effect on 1-year mortality and 
cardiovascular events (RR, 0.61; 95% CI, 0.40 to 0.91; P=0.015). Although stroke rates were not 
changed, cerebrovascular revascularization procedures were reduced by half.  
 
Dyslipidemia 
Total Cholesterol 
Most but not all epidemiological studies find an association between higher cholesterol levels and 
an increased risk of ischemic stroke. In the Multiple Risk Factor Intervention Trial (MRFIT), which 
included >350 000 men, the relative risk of death from nonhemorrhagic stroke increased 
progressively for each level of cholesterol.  In the Eurostroke Project of 22 183 men and women, 
there was no relationship between cholesterol with cerebral infarction (171). Overall, 
epidemiological studies suggest competing stroke risk related to total cholesterol levels in the 
general population; high total cholesterol may be associated with higher risk of ischemic stroke, 
whereas lower levels are associated with higher risk of brain hemorrhage (171-186).  
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HDL Cholesterol 
Most but not all epidemiological studies show an inverse relationship between high-density 
lipoprotein (HDL) cholesterol and stroke (187). HDL cholesterol was inversely related to ischemic 
stroke in the Copenhagen City Heart Study, the Oyabe Study of Japanese men and women, middle-
aged British men, and middle-aged and elderly men in the Israeli Ischemic Heart Disease Study 
(188-191). 
 
Triglycerides 
The results of epidemiological studies that have evaluated the relationship between triglycerides and 
ischemic stroke are inconsistent, in part because some have used fasting levels and others nonfasting 
levels. The Copenhagen City Heart Study, a prospective, population-based cohort study composed 
of approximately 14 000 persons, found that elevated nonfasting triglyceride levels increased the 
risk of ischemic stroke in both men and women (192). Similarly, the WHS found that in models 
adjusted for total and HDL cholesterol and measures of insulin resistance, nonfasting triglycerides, 
but not fasting triglycerides, were associated with cardiovascular events, including ischemic stroke 
(193). 
 
Atrial Fibrillation 
Atrial fibrillation, even in the absence of cardiac valvular disease, is associated with a 4- to 5-fold 
increased risk of ischemic stroke due to embolism of stasis-induced thrombi forming in the left atrial 
appendage (194). Embolism of appendage thrombi associated with atrial fibrillation accounts for 
about 10% of all ischemic strokes and an even higher fraction in the very elderly in the United 
States (195). The absolute stroke rate averages about 3.5% per year for persons aged 70 years with 
atrial fibrillation, but the risk varies 20-fold among patients depending on age and other clinical 
features (see below) (196,197). Atrial fibrillation is also an independent predictor of increased 
mortality (198). Paroxysmal atrial fibrillation is associated with an increased stroke risk that is 
similar to that of chronic atrial fibrillation (199).  
 
Other Cardiac Conditions 
Cardiogenic embolism is the cause of approximately 20% of ischemic strokes (200). Cardioembolic 
strokes are relatively severe, are associated with greater neurological deficits at admission, greater 
residual deficits at discharge, and greater neurological deficits after 6 months compared with 
noncardioembolic strokes (202). Cardiac conditions associated with a high risk for stroke include 
atrial arrhythmias (eg, atrial fibrillation/flutter, sick sinus syndrome), left atrial thrombus, primary 
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cardiac tumors, vegetations, and prosthetic cardiac valves (201). Other cardiac conditions that 
increase the risk of stroke include dilated cardiomyopathy, coronary artery disease, valvular heart 
disease, and endocarditis. Stroke may occur in patients undergoing cardiac catheterization, 
pacemaker implantation, and coronary artery bypass surgery (203,204).  
The incidence of stroke is inversely proportional to left ventricular ejection fraction (205-207). 
Patients with rheumatic mitral valve disease are at increased risk for stroke (208). Mitral 
valvuloplasty does not eliminate this risk (209). Thromboembolic events have been reported in 
association with and attributed to mitral valve prolapse when no other source could be identified 
(210). Patients with mitral annular calcification are predisposed to embolic phenomena, particularly 
in older patients with dense calcifications (211). Systemic embolism from isolated aortic valve 
disease may also occur (211). It is less frequent in the absence of associated mitral valve disease or 
atrial fibrillation (212). Multiple mechanical prosthetic valves are currently available and deployed 
(208). The intensity of anticoagulation should be proportional to the thromboembolic risk of the 
individual mechanical prosthetic valve (208). Ischemic stroke occurs in 15% to 20% of patients with 
infective endocarditis (213,214). Mitral valve endocarditis carries the greatest stroke risk (213). The 
management of endocarditis is directed at the underlying etiology.  
Cardiac tumors are uncommon and account for a very small minority of embolic events (215,216). 
Congenital cardiac anomalies, such as patent foramen ovale (PFO), atrial septal defect, and atrial 
septal aneurysm, can be associated with stroke, especially in younger patients (see sections on 
migraine and coagulopathy) (217-219). Meta-analysis of case-control studies focused on patients 
who have had a stroke found an increased risk in those <55 years of age (for PFO: OR, 3.10; 95% 
CI, 2.29 to 4.21; for atrial septal aneurysm: OR, 6.14; 95% CI, 2.47 to 15.22; and for PFO plus atrial 
septal aneurysm: OR, 15.59; 95% CI, 2.83 to 85.87) (220). In contrast, population-based studies find 
no increased risk of a first stroke associated with PFO (221,222).  
 
Asymptomatic Carotid Stenosis 
The presence of an atherosclerotic stenotic lesion in the extracranial internal carotid artery or carotid 
bulb has been associated with an increased risk of stroke.  
Assessment of Carotid Stenosis 
A "hemodynamically significant" carotid stenosis produces a drop in pressure, a reduction in flow, 
or both. This generally corresponds to a 60% diameter–reducing stenosis as measured by catheter 
angiography using the North American Symptomatic Carotid Endarterectomy Trial (NASCET) 
method (223). The NASCET method measures the minimal residual lumen at the level of the 
stenotic lesion compared with the diameter of the more distal internal carotid artery, where the walls 
of the artery become parallel. The following formula is used: stenosis=(1–R/D)x100%.  
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Sickle Cell Disease 
Sickle cell disease (SCD) is an autosomal recessive inherited disorder in which the abnormal gene 
product is an altered hemoglobin β-chain. Although the clinical manifestations are highly variable, 
SCD typically manifests early in life as a severe hemolytic anemia with painful episodes involving 
the extremities and bones ("vaso-occlusive crises"), bacterial infections, and organ infarctions, 
including stroke. Other effects include cognitive deficits related to MRI-demonstrated strokes and 
otherwise asymptomatic white matter hyperintensities (224,225).  
 
Postmenopausal Hormone Therapy 
The Women's Health Initiative (WHI), a randomized trial of conjugated equine estrogens (CEE) 
combined with medroxyprogesterone acetate (MPA) versus placebo in women 55 to 79 years of age 
(226), has had a profound impact on the practice of prescribing these therapies to postmenopausal 
women (227). Additional analyses of the WHI focused on specific subgroups of women to 
determine those at particularly high risk (228). The risk of stroke with CEE was limited to ischemic 
(HR, 1.55; 95% CI, 1.19 to 2.01) and not hemorrhagic stroke (HR, 0.64; 95% CI, 0.35 to 1.18). 
There was no difference based on stroke etiologic subtype, severity, or mortality (228).  
An analysis of the Nurses' Health Study reported similar findings: women using hormone therapy 
had an increased risk of stroke regardless of age at initiation or years since menopause (229).  
 
Oral Contraceptives 
The risk of stroke associated with use of OCs is low. Certain women, particularly those who are 
older; who smoke cigarettes; and who have hypertension, diabetes, obesity, hypercholesterolemia, 
and prothrombotic mutations may be at higher risk. Estimates are based primarily on case-control 
studies and a smaller number of cohort studies, both of which are limited by small numbers of 
women with stroke events. The incremental risk of stroke associated with use of low-dose OCs in 
women without additional risk factors, if one exists, appears to be low (230,231) 
 
 
 
Diet and Nutrition 
A large and diverse body of evidence has implicated several aspects of diet in the pathogenesis of 
high BP, the major modifiable risk factor for ischemic stroke. A recent AHA scientific statement 
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concluded that several aspects of diet lead to elevated BP (232), specifically, excess salt intake, low 
potassium intake, excess weight, high alcohol consumption, and suboptimal dietary pattern.  
In observational studies, several aspects of diet are associated with risk of stroke. A meta-analysis 
found a strong, inverse relationship between servings of fruits and vegetables and subsequent stroke 
(233).  
The effects of sodium and potassium on stroke risk are likely mediated through direct effects on BP, 
as well as mechanisms that are independent of BP (234).  
 
Physical Inactivity 
Physical inactivity is associated with numerous adverse health effects, including an increased risk of 
total mortality, cardiovascular mortality, cardiovascular morbidity, and stroke. The 2008 Physical 
Activity Guidelines for Americans provides an extensive review and concludes that physically 
active men and women generally have a 25% to 30% lower risk of stroke or death than the least 
active people (235).  
The protective effect of physical activity may be partly mediated through its role in reducing BP 
(236) and controlling other risk factors for CVD (237,238),  including diabetes (236), and excess 
body weight. Other biological mechanisms have also been associated with physical activity, 
including reductions in plasma fibrinogen and platelet activity and elevations in plasma tissue 
plasminogen activator activity and HDL-cholesterol concentrations (239-241).  
 
Obesity and Body Fat Distribution 
A large number of prospective studies have examined the relationship between weight (or measures 
of adiposity) and incident stroke. A meta-analysis found a nonlinear association between BMI and 
mortality (242). In the BMI range of 25 to 50 kg/m2, each 5 kg/m2 increase in BMI was associated 
with a 40% increased risk of stroke mortality; in the lower BMI range (15 to 25 kg/m2), there was no 
relationship between BMI and stroke mortality, even after excluding smokers.  
The effect of BMI on stroke risk is in part mediated by the effect of adiposity on other stroke risk 
factors.  
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Less Well-Documented or Potentially 
Modifiable Risk Factors 
 
Migraine 
Migraine headache has been most consistently associated with stroke in young women (<55 years of 
age), especially those with migraine with aura (243).  
 
Alcohol Consumption 
Excessive consumption of alcohol can lead to multiple medical complications, including stroke. 
Strong evidence exists that heavy alcohol consumption is a risk factor for all stroke subtypes (244-
248). Most studies suggest a J-shaped association between alcohol consumption and the risk of total 
and ischemic stroke, with a protective effect in light or moderate drinkers and an elevated risk with 
heavy alcohol consumption (101,244,245,249-256). In contrast, a linear association exists between 
alcohol consumption and risk of hemorrhagic stroke (103,151,257,258).  
Light to moderate alcohol consumption, particularly in the form of wine, is associated with reduced 
risk of total and ischemic stroke since determines greater levels of HDL cholesterol (259-260), 
reduced platelet aggregation (262,263), lower fibrinogen concentrations (264,265), and increased 
insulin sensitivity and glucose metabolism (266). Heavy alcohol consumption increases risk of 
stroke given that can result in hypertension, hypercoagulability, reduced cerebral blood flow, and 
increased risk of atrial fibrillation (245,250,252,265,267).  
are no controlled trials demonstrating a reduction in stroke risk with abstinence.  
 
Sleep-Disordered Breathing 
Epidemiological studies suggest that habitual snoring is a risk factor for ischemic stroke, 
independent of confounding factors such as hypertension, ischemic heart disease, obesity, and age 
(268,269). Loud snoring is associated with an increased risk of carotid compared with femoral 
atherosclerosis (OR, 10.5; 95% CI, 2.1 to 51.8; P=0.004) independent of other risk factors, 
including measures of nocturnal hypoxia and severity of obstructive sleep apnea (270). Consistent 
with these observations, a 10-year observational study of 1651 men found that severe obstructive 
sleep apnea-hypopnea (according to the apnea-hypopnea index, >30 occurrences per hour of sleep) 
increased the risk of fatal (OR, 2.87; 95% CI, 1.17 to 7.51) and nonfatal (OR, 3.17; 95% CI, 1.12 to 
7.52) cardiovascular events (MI, acute coronary insufficiency requiring coronary artery bypass 
surgery and/or percutaneous transluminal angioplasty, and stroke) as compared with healthy 
participants (271). A 6-year longitudinal prospective study of 394 noninstitutionalized, initially 
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event-free subjects (70 to 100 years of age, median 77.28 years, 57.1% male) found that severe 
obstructive sleep apnea-hypopnea (defined as apnea-hypopnea index 30) increased the risk of 
ischemic stroke independent of known confounding factors (272).  
sleep-disordered breathing (SDB) SDB can increase stroke risk by leading to or worsening 
hypertension and heart disease and possibly by causing reductions in cerebral blood flow, altered 
cerebral autoregulation, impaired endothelial function, accelerated atherogenesis, 
hypercoagulability, inflammation, and paradoxical embolism in patients with patent foramen ovale 
(272-275).  
 
Hyperhomocysteinemia 
Homocysteine is an amino acid that is derived from the metabolism of the essential amino acid 
methionine. Increased plasma levels of homocysteine are often a consequence of reduced enzymatic 
activity in its metabolic pathways. This may be caused by genetic defects in the enzymes involved 
in homocysteine metabolism, sed by nutritional deficiencies of pyridoxine (vitamin B6), of folic acid 
and cobalamin (vitamin B12). Decreased renal clearance of homocysteine in patients with chronic 
renal failure may contribute to hyperhomocysteinemia.  
Elevated levels of plasma homocysteine are associated with a 2- to 3-fold increased risk for 
atherosclerotic vascular disease, including stroke (276-282).  
 
Inflammation and Infection 
Stroke risks is associated with several inflammatory conditions and markers. Inflammation affects 
the initiation, growth, and destabilization of atherosclerotic lesions (283). A number of serum 
markers of inflammation, including fibrinogen, serum amyloid A, Lp-PLA2, and interleukin 6 have 
been proposed as risk markers. Several studies suggest a relationship between Lp-PLA2 and stroke 
risk (approved by the US Food and Drug Administration as a predictor of ischemic stroke and 
coronary artery disease), (284-286) with high-sensitivity C-reactive protein (hs-CRP) being the 
most commonly used (287). In addition to numerous epidemiological studies and randomized 
clinical trials with coronary disease end points, several epidemiological studies have identified 
associations between hs-CRP and stroke, including the Physician's Health Study (288), the WHS 
(289), and the Framingham Heart Study (290).  
Another way to evaluate the role of inflammation as a risk factor for stroke is to examine the 
incidence of vascular disease in persons with systemic chronic inflammatory diseases, such as 
rheumatoid arthritis (RA) and SLE. A large number of prospective cohort studies have identified 
increased risks for CVD (including stroke) in persons with RA, with odds ratios consistently in the 
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1.4 to 2.0 range compared with persons without RA (292-296). Excess risk was especially apparent 
in women with RA who were 35 to 55 years of age (292). This association remained after 
adjustment for other cardiovascular risk factors. Similarly, patients with SLE had very elevated 
relative risks for CVD in the 2- to 52-fold range (297). Although stroke rates were not assessed, 
several studies have identified a higher prevalence of atherosclerotic plaque in the carotid arteries of 
patients with RA or SLE compared with control subjects (298-300).  
A final issue in the role of infection and inflammation in stroke deals with the role of acute 
infectious diseases (eg, influenza) inducing a cerebrovascular event (TIA or stroke). Possible 
mechanisms include the induction of procoagulant acute phase reactants (eg, fibrinogen) or the 
destabilization of atherosclerotic plaques. An increase in cardiovascular deaths has long been 
observed in association with influenza (301,302). 
 
Psychosocial Behaviors and Risk 
It has been suggested that psychosocial well-being interacts with biological factors to influence risk 
of disease. Longitudinal studies provide an appropriate venue to follow the association between 
psychosocial well-being and health behaviors over a sufficient length of time to observe the 
relationship, interactions, and effect on health and disease. Evidence derived from longitudinal 
studies has demonstrated that marital strain, job stress, and depression are associated with coronary 
heart disease, mortality, and stroke (303-305). Depression has been associated with unhealthy 
behaviors such as inactivity, change in diet, and smoking (306,307), and starting in middle age, its 
presence has been associated with risk of stroke in men and women (306). 
A new model for novel risk factor interaction is currently evolving around the association between 
social connections and health behaviors.  
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THE GEHA PROJECT 
 
The origins of the GEHA Project 
Europe is the oldest continent and in the last decade the number of people aged more than 90 years 
is rapidly rising. The actual proportion of people with more than 90 years is about 50% of the total 
population. There is a small proportion of elders that apparently undergoes an aging process and 
they surprisingly appear deprived of the most common age-related disease (cardiovascular disease, 
stroke, II type diabetes, cancer and dementia). In this scenario it is important to study causes and 
mechanisms of the aging, that in 2001 the 5-year European Union Integrated Project GEnetics 
of Healthy Aging (GEHA) born. The most important aim of this study is to identify genes involved 
in healthy aging and longevity, which allows individuals to reach advanced old age in good 
cognitive and physical conditions, without the major age-related diseases.  
The GEHA Project represents the strongest and the most competitive consortium ever realized in 
Europe to investigate genetic bases of human aging process, capable of reaching results that is 
impossible to obtain in a single European country. 
The 5-year GEHA Project is supported through Priority 1 (Life Sciences, Genomics and 
Biotechnology for Health) of EU’s FP6 (Project Number LSHM-CT-2004-503270) and approved 
by European Commission. The project started on May 1, 2004 and ended ion April 30, 2010 (with a 
1-year delay). 
 
The GEHA Consortium and its Bodies 
The GEHA project is a large consortium of 25 partners (24 partners from Europe and 1 partner 
from China). All these countries have traditions and laws quite different regarding privacy 
protection, ethical recommendations for genetic studies, access to demographic sources, Intellectual 
Property Rights (IPR) rules, among others. The GEHA project regarding the genetics of human 
longevity requires the recruitment of very old sibpairs and the donation of their blood or other 
biological material on which to carry out the genetic analysis. Thus, GEHA deals with sensitive 
issues (ethics, privacy, etc.), which requires as much attention and care as possible. For all these 
reasons, the first phases of the project were devoted to the standardization of all the necessary tools, 
and the fulfilment or ethical requirements both essential to start the recruitment of 90+ sibpairs and 
younger controls. A great effort was done to overcome the heterogeneity of the legislations 
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established in the various countries involved in the project to guarantee the respect of privacy and 
confidentiality laws of the European citizens involved in the project. 
In order to fulfil all the scientific, ethical, financial, and IPR requirements, and following the 
guidelines of the EU, the GEHA project was endowed with a complex organization structure 
composed by the following bodies: 
Coordinator: Professor Claudio Franceschi; Project Manager: Dr. Alessandra Malavolta; Scientific 
Manager: Dr. Silvana Valensin; 
General Assembly (GA) composed by 25 members (i.e., all the Principal Investigators, one person 
per Partner); 
Steering Committee (SC) composed by 9 members (i.e., the leaders of the 12 Work Packages); 
Ethics Steering Group (ESG) composed by 3 internal members plus 2 external members; 
External Advisory and Gender Board (EAGB) composed by eminent scientists from the United 
States and Europe; 
Legal and IPR Board (LIPR) composed by 3 members; 
Financial Management Board (FMB) composed by 5 members. 
 
 
 
 
The Institutions (Principal Investigator in parentheses) constituting the GEHA Consortium are: 
(1) UNIBO-CIG, Interdepartmental Centre “L.Galvani,” University of Bologna, Italy (Claudio 
Franceschi); 
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(2) CRLC, Department of Biostatistics, University of Montpellier, Val d’Aurelle Cancer Research 
Center, Montpellier, France (Jean Marie Robine); 
(3) CAU, Kiel Center for Functional Genomics, University Hospital Schleswig Holstein, Kiel, 
Germany (Stefan Schreiber); 
(4) CEPH, Centre Polymorphisme Humaine, Fondation Jean Dausset, Paris, France (Hélène 
Blanché); 
(5) ISS, Istituto Superiore di Sanità, Rome, Italy (Maria Antonietta Stazi); 
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The Major Objectives of the GEHA Project 
Europe is the oldest continent and is rapidly aging. Currently, the percentage of people in the EU 
who are 90 years old or older is about half a percent, with 90+ year-old-males comprising 0.29% of 
the male population and 90+ year-old-females 0.88% of the female population (data of 2003). Even 
if, collectively, age-related diseases (cardiovascular diseases, stroke, type II diabetes, camcer and 
dementia) affect most of the elderly, there is a minority which apparently undergoes an aging 
process that is free from such diseases (“successful” or “healthy” aging). The objective of the 
GEHA project is to identify genes that influence healthy aging and longevity in humans, and that 
protect individuals from major age-related diseases and disabilities, thus allowing them to survive to 
advanced old age in good cognitive and physical condition. 
Accordingly, the major goals of the GEHA project are the following: 
(1) To overcome the fragmentation of the research on the genetics of aging in Europe; 
(2) To set up a coherent, tightly integrated program of research that unites demographers, 
geriatricians, geneticists, genetic epidemiologists, molecular biologists, bioinformaticians and 
statisticians; 
(3) To recruit an unprecedented number of long-living sibpairs (n = 2650) both aged 90 years of age 
or more (90+) from 11 European countries in 15 geographic areas; 
(4) To perform a genome-wide scan on the DNA of all recruited sibpairs (Affected SibPair analysis, 
ASP analysis) in order to identify chromosomal regions involved in longevity and healthy aging; 
(5) To recruit a large number (n = 2650) of ethnically-matched control subjects (50–75 years of 
age) from the same geographic areas, necessary to fine-map the chromosomal regions identified by 
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ASP analysis and the three candidate chromosomal regions (see n.8), and to allow large scale 
association studies;  
(6) To perform bioinformatics, functional genomics, proteomics and molecular biology studies on 
the identified/putative longevity regions/genes and gene variants resulting from ASP analysis and 
LD mapping; 
(7) To test whether ethnically different European populations (including those from Sardinia and 
Finland) share the same genes involved in aging and longevity; 
(8) To ascertain the role played in human longevity by three candidate regions (D4S1564 in 
chromosome 4, 11p15.5 in chromosome 11 and around the ApoE gene in chromosome 19) once 
ascertained the LD block structure in CEPH families; 
(9) To verify in a variety of European populations and at a large scale the role of mitochondrial 
DNA (mtDNA) germline variants (haplogroups, subhaplogroups), and mutations (C150T) in human 
longevity, and to study their interaction with the newly emerging longevity nuclear genes; 
(10) To identify gender-specific genes differently involved in the healthy aging and longevity of 
women and men; 
(11) To stratify the samples according to ApoE genotype, i.e. the only genetic marker which so far 
has been found to be associated with reduced longevity in a variety of populations; 
(12) To develop innovative analytical strategies (based on statistical method and mathematical 
models) capable of combining all the data collected (demographic, clinical, socio-economical, 
genetic and related to lifestyle), to highly increase the power of genetic analysis; 
(13) To perform a longitudinal study to evaluate the importance of genetic factors on mortality of 
the recruited 90+ sibpairs. 
GEHA Databases 
The GEHA project highly depends on a complex bioinformatics environment that ensures full 
availability of samples, phenotypes and molecular data to the Partners, but also ensures data privacy 
to the participating EU citizens. In order to fulfil the requirements related to privacy protection, 
security, easy access and implementation, GEHA envisages a peculiar centralization of the different 
types of data collected. Indeed, the three main types of GEHA data (phenotypic, genetics and 
related to the mtDNA) are stored on three physically separate servers: 
- the Phenotypic Database (containing clinical and demographic data on the basis of GEHA 
questionnaires) is localized in Odense (Denmark); 
- the Genotypic Database (containing genotyping data) is localized in Kiel (Germany); 
- the mtDNA Database (containing data related to mtDNA) is localised in Tampere (Finland). 
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Thus, these geographically separated databases strictly separate phenotype data (phenotype 
database and phenotype server) and genotyping data (genotyping database and server). However, 
they are largely interconnected: this peculiar structure allows GEHA Partners to perform all types of 
analysis (cross-analysis) and at the same time it protects privacy.  
The general criteria of GEHA databases can be summarised as follow: not access from outside, air 
conditioned system, localization in locked server room, daily backups and networks protected by a 
firewall. 
As regards the Phenotypic Database:  
• Data are entered using the PC application EPIDATA on the server; 
• Each centre enter locally all the data related to each recruited subject; 
• EPIDATA provides immediate validation while entering data (Web solutions will NOT give 
immediate validation); 
• The system speed is satisfactory; 
• Access of several users contemporary (tested with 5 users); 
• Central backup of the data; 
• Access control: each partner can only access his own data; 
• EPIDATA stores data in text files (ability to track changes in data and easier merging of the data 
from the different centers);• The Oracle application makes it possible to download and view your 
own data. 
The Genotypic Databases was built up for high throughput SNP genotyping and for the storage of 
genotype data, such as chromosome, locus, oligo sequences and genotypes. 
As regards the mtDNA Database, it should be remembered that the GEHA consortium will 
eventually match all the data obtained on mtDNA genetics with those obtained as a result of the 
genotyping of the nuclear genome, in the 90+ sibpairs and in the controls. For this purpose, a new 
database was created in order to allow storage, retrieval, and analysis of all the collected mtDNA as 
well as the cross-matching of these data with those coming from the nuclear DNA genotyping. This 
database will represent one of the largest collection of mtDNA sequence data, and by adding to it 
other already published sequences will constitute one of the largest mtDNA database worldwide. 
The consortium will also work to implement in the database some new functions which are 
currently not available in any other mtDNA database such as the automatic haplogroups 
classification. This feature is the first step into the direction of making such a software a permanent 
service available, in due time, to any other user worldwide. 
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The GEHA design and the genetic analysis (nuclear and 
mitochondrial genome) 
GEHA genome-wide linkage scanning 
In the last few years an enormous amount of data became available regarding the human genome, 
including data on millions of new single-nucleotide polymorphism (SNP) variants in different 
human populations (HAPMAP Project). Such an unprecedented extremely fast progress has been 
possible owing to the continuous refinement of the genetic methodologies as well as the methods of 
data analysis. Concomitantly, the conceptualisation about genome-wide studies, their possibilities 
and limitations, has also progressed in a very fast way so that the entire scenario of genetic studies 
on complex traits has completely changed. 
The GEHA project took an enormous advantage from such a rapid advancement in the field and the 
GEHA geneticists, after a careful examination of the most recent available literature in the field, 
decided the genetic strategy and the platform to adopt according to reliability of the results, cost per 
SNPs and technician time, as well as the direct experience and the expertise of the GEHA partners. 
Even if the main goal of the GEHA project is to perform a Linkage analysis with several thousand 
of highly informative SNPs using the 2650 90+sibpairs, it is important to stress that the GEHA 
design allows to perform both linkage and association studies (using one member of the sibship and 
the younger unrelated control), according to the most advanced genetic approaches to complex 
traits, as illustrated in Figure 5. These possibilities (genome-wide genetic association studies) might 
be pursued in future developments/continuation of the project, using the unique collection of DNA 
samples recruited by the GEHA consortium. 
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Figure 5. The design of the GEHA project allows to perform either genome-wide linkage studies, 
using the DNA collected from the 2650 90+ sibpairs, or association studies using the DNA 
collected from one (or both) member of each sibship and the DNA collected from the unrelated, 
ethnically matched younger control. The association studies can be either genome-wide or focused 
on specific chromosal region(s) or loci. 
 
Indeed, linkage studies on large samples of extreme long-lived siblings may be among the best 
approaches to identify longevity genes. Linkage analysis looks for coinheritance of chromosomal 
regions with the trait in families, and it is more powerful than association analysis for identifying 
rare high-risk disease alleles. Association is an approach to gene mapping that looks for 
associations between a particular phenotype and allelic variation, that is, for differences in the 
frequency of genetic variants between unrelated affected individuals and controls, with the 
expectation that the risk-conferring allele (haplotype) will be more common in cases (the long-
living people) than in controls (the younger subjects). Association analysis nowadays can be 
performed genome-wide and it is expected to be more powerful for the detection of common alleles 
that confer modest disease risks. The advantage of linkage studies is that they are less influenced by 
population admixture than the association approach, while the advantage of association case–
control studies is that they require much less genotyping to obtain equivalent power. Within an 
evolutionary and Systems Biology perspective longevity likely results from the interaction and 
cross-talk between two genomes: (a) the Nuclear genome; and (b) the Mitochondrial genome 
(mtDNA). Accordingly a major aim of GEHA is to ascertain the role of mtDNA inherited as well as 
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epigenetic variability in human longevity taking advantage of the unprecedented number of very old 
sibpairs recruited by GEHA, belonging to different European populations.  
 
The analysis of mtDNA variability 
The GEHA consortium has the capacity to provide the largest dataset on mtDNA variation over age 
in different populations. To this purpose the main activities will be the following : 
(1) mtDNA Resequencing 
Different approaches were developed by the GEHA consortium in order to obtain complete mtDNA 
sequencing. A strategy of quality control of the sequences and the design of a database for the 
storage and analysis of the sequences and their annotation were developed. mtDNA belonging to 
the specific populations will be resequenced for a total of about a thousand mtDNA sequences. All 
other GEHA samples will be genotyped for mtDNA haplogroups and subhaplogrops, using a 
protocol based on polymerase chain reaction (PCR) amplification and sequencing of the mtDNA D-
Loop together with some principal restriction sites. An appropriate database for storage and 
analysis of mtDNA genetic data will be developed. 
(2) Analysis of C150T Mutation 
A fast and relatively cheap DHPLC technique to screen heteroplasmy in the whole mtDNA molecule 
was developed. This will allow to analyse possibly identified common “hot spots” of heteroplasmy 
(including the C150T mutation) in a large group of sibpairs and controls.  
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GEHA QUESTIONNAIRES 
 
a) 90+ siblings questionnaire 
The aim of the questionnaires is to obtain information making it possible to classify the long-lived 
participants in three main groups based on their functional capabilities: those with an exceptionally 
good health status, those with a poor health status, and the group in between. This classification will 
subsequently be the basis for the analyses of the relation between healthy aging and genetic factors.  
The GEHA questionnaire for 90+ sibpairs was built on several years of direct experience that many 
members of the GEHA Consortium have in the assessment of the health status, interviewing and 
recruiting very old people in the course of a variety of studies performed on nonagenarians and 
centenarians in several European countries, including EU ECHA project, which included interviews 
and health status assessment of extremely long-lived people in Italy, France and Denmark. Some of 
the members of the GEHA Consortium were indeed the first to propose a classification of 
centenarians based on their health status assessed on the basis of objective and quantitative criteria 
(27).  
A starting point of the discussion on the type of questionnaire to be adopted was a critical 
evaluation of all the available questionnaires adopted until 2004 in studies on the oldest old. This 
critical evaluation arrived to the conclusion that most of the questions posed to very old people in 
the various questionnaires were apparently useless and they have never been used later on because 
they refer to poorly quantifiable trait or ambiguous questions. Moreover, a trade-off likely occurs 
between the number of questions or items in the questionnaire and the reliability of the responses 
obtained. Last but not least, all the GEHA partners involved in the recruitment agreed that for 
practical reasons (fatigue of the 90+ people; rate of acceptance of the blood donation) it was 
unacceptable an interview which would last more than 90 minutes maximum. Thus a particular 
effort was devoted to include in the questionnaire for 90+ sibpairs only critical items suitable to 
help defining the health status of the oldest old, and to eliminate any ambiguous, poorly quantifiable 
or likely unreliable item, which most probably would result useless in the final merging of 
phenotypic data with the genetic ones.  
The questionnaire for the 90+ sibpairs includes questions on family composition, marital status, 
education (according to the ISCED classification), occupation (according to ISCO-88(COM) 
classification), and housing conditions.  
Functional capability is assessed by Katz’s Activity of Daily Living (ADL) (306) and by questions 
about functional limitations from the Nagi-scheme (reading ability, hearing ability, 500 metres 
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walking ability without aids, going up and down the stairs without anyone’s help, light daily 
exercise and going outside with or without anyone’s help) (307).  
Cognitive function is assessed by the standardized Mini Mental State Examination (SMMSE) 
(309).  
Health status is assessed by a series of questions concerning present and past diseases, and a single 
question regarding self-perceived health. Also included are a few questions about tobacco and 
alcohol use.  
Finally physical performance is tested by two simple tests: measurement of handgrip strength and 
five time chair stand. Height and weight are mostly self-reported, and in some labs directly 
measured. 
 
b) Controls Questionnaire 
The questionnaire for the younger controls was a subset of the questionnaire to the old siblings. The 
most important part of this questionnaire is a part illuminating the genetic background of the 
younger controls: they should comprise a group with a similar genetic composition as the old 
siblings. Apart from this a few questions about health and life style factors were included, but no 
assessment of physical, functional or cognitive function is performed. 
 
c) Family Questionnaire 
The information for the old siblings is at two levels: the individual level, and the family level, 
information common to siblings. This last level contains information about parents and 
grandparents, and about other siblings.  
A separate questionnaire for obtaining family information was prepared, including questions about 
the parents and their origin, and about the other siblings.  
 
SURVIVAL ANALYSIS 
For the survival analysis, the vital status of the recruited 90+ sibpairs and younger controls was 
checked at January 1st, 2009 and an official certificate of the vital status was collected from the 
Register Office of the Municipalities of residence of the 90+ sibpairs. 
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MATERIALS AND METHODS. 
 
POPULATION 
 
Our sample consists of the 90+ sibs (Total 1176, 801 females, 375 males) collected from the 3 
Italian Recruiting Units of the GeHA project.: 
• University of Bologna (UNIBO) (549 subjects, 385 females and 164 males): mainly 
collected subjects from North Italy, mainly from Bologna area; 
• Istituto Superiore di Sanità (ISS) (216 subjectes, 158 females and 58 males): collected 
subjects from Rome area (Central Italy) 
• University of Calabria (RC) (411 subjects, 258 females and 153 males): Collected samples 
from the Calabria Region (South Italy) 
This population contains all 90+ siblings that were interviewed and whose phenotype data were 
entered in the GEHA Phenotypic Database (localised in Odense, Denmark). 
The local Ethical Committees approved the study. 
 
CLASSIFICATION OF THE 90+ SIBS IN THE STUDY 
 
1) PROXY INTERVIEW 
A proxy-responder was encouraged to participate in the interview if the nonagenarian was unable to 
participate due to mental or physical handicaps.  
Proxy interviews have been performed for the reason that in some families one of the siblings had 
poor cognitive and/or functional status, even if it’s sibling(s) were in a good status. 
Proxy interview data are reported to the “Results” section, even if we decide to not use these data 
for the rest of the analysis, in order to avoid bias from the extreme disability (cognitive and 
functional deficit) that the proxy interview 90+ sib is affected. 
 
2) STROKE 
We have divided pour sample in three main categories according their answer in the 55c question 
of the 90+ sibs questionnaire (“Have you ever had one or more of the following diseases? Stroke, 
cerebral thrombosis/haemorrhage. If “yes”, report age of first time”). 
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a) Stroke free: negative answer in the 55c question (960 subjects, 88.72%). 
b) Young age stroke: positive answer in the 55c question (42 subjects, 3.88%). Reported age of 
Stroke incidence < 85 y.o. 
c) Old age stroke: positive answer in the 55c question (80 subjects, 7.39%). Reported age of 
Stroke incidence ≥ 85y.o. 
3) COGNITIVE STATUS 
Cognitive function was measured using the Standardized Mini-Mental State Examination 
(SMMSE) (310).  
The raw SMMSE score was adjusted for age and years of education according to the reference 
given by Magni et al. 1996 in a study on Italian population, as reported in Table 1, and our sample 
has been classified in two groups:  
i) Normal cognitive status (MMSE ≥24) 
ii) Cognitive Impairment (MMSE < 24) 
Since no validated adjustment coefficients are available for subjects aged more than 90 years, we 
included 90+ subjects in the last category proposed by Magni et al. (85-89 years) (309). 
Age-range 65-69 70-74 75-79 80-84 85-89 
Education      
0-4 years +0,4 +0,7 +1,0 +1,5 +2,2 
5-7 years -1,1 -0,7 -0,3 +0,4 +1,4 
8-12 years -2,0 -1,6 -1,0 -0,3 +0,8 
13-17 years -2,8 -2,3 -1,7 -0,9 +0,3 
Coefficients are to be added (or subtracted) to the raw SMMSE score to obtain the adjusted SMMSE score 
Moreover we took under consideration the items regarding the cognitive efficiency like the ability 
to understand the questions or the presence of serious memory impairments like dementia 
4) DISABILITY 
Questions in this area covered the Katz Index of activities of daily living (ADL) - bathing, dressing, 
toileting, transfer, feeding and continence. 
Using the ADL scale we have divided our sample in: 
- ADL independent (ADL score 5-6).  
- ADL moderate dependent (ADL score 3-4).  
Furthermore, we examine the presence of arthritis, capability to walk 500m without any help, daily 
exercise or daily light housework to assess the disability status of our population. 
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5) MEASURES OF PHYSICAL PERFORMANCE 
Ability to perform a five times chair stand test and Handgrip strength and were included in the 
study. 
In the chair stand test, participants were divided in two groups (able to complete the test and unable 
to complete the test). 
Handgrip strength was measured using a hand-held dynamometer (SMEDLYS’ dynamometer, 
Scandidact, Kvistgaard, Denmark) for two performances with each hand. Also in this test 
participants were divided in two groups (able to complete the test and unable to complete the test). 
 
6) LIFE STYLE FACTORS 
Participants were classified as smokers, former smokers, or never smokers. Moreover, the cases of 
consumption of alcohol every day were recorded, but not the quantity of alcohol intake. 
 
7) SURVIVAL ANALYSIS 
Vital status for the total cohort was assessed at January 1st 2009.  
 
NOTE: Differences in the number of cases are due to the presence of missing values. 
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STATISTICAL ANALYSIS 
 
Univariate analysis. 
ii) Chi-square test or Fisher’s Exact test (on the basis of the number of observations) were 
used to analyse categorical variables (gender, type of interview, ADL scale categories). 
iii) Student t test was used to compare scores of continuous variables (SMMSE, Hand Grip).  
iv) Odds Ratio and 95% Confidence Intervals were calculated in order to compare groups.  
 
Multivariate analysis 
ii) Logistic regression was performed in order to evaluate the risk of disability (low MMSE 
score, low ADL score, incapacity to perform hand grip or chair standing test) and 
occurrence of stroke at a certain age. 
 
Survival Analysis 
i) Cox regression-based test for equality of survival curves was used to compare the mortality 
risk in different groups of subjects. 
 
All the analysis were performed using Stata version 9.0 (Stata Corp., College Station, TX).  
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RESULTS 
 
Preliminary remarks:  
In this statistical analysis we considered the age of the interview, the reported age of the first stroke 
event and some additional variables. These variables have been selected because they could 
represent cerebrovascular disease risk factors (Sex, Age, Smoke habit, Alcohol consumption, lack 
of exercise), cognitive and disability indicator (ability to understand the questions, presence of 
serious memory impairments like dementia, presence of arthritis, capability to walk 500m without 
any help, daily exercise or daily light housework).  
Moreover, we considered the age of 85 y.o as the cut-off for the reported age of the first stroke 
event since from this age on many population and aging studies, have demonstrated a shift in the 
importance of the classic metabolic risk factors. 
 
Our sample consists of 1176 subjects: 801females (68,11%)  and 375 males (31,89%), between 90-
105 years old recruited in three centres (Table 1 : Sex Distribution). Applying the Two-sample t test 
no differences in the age distribution have been found between the centres. (Table 1 : Age 
Distribution). 
 
Table 1 : Sex Distribution 
 
Sex 
Center 
Total 
UNIBO ISS UNICAL 
Male 
164 
29,87 % 
58
26,85 %
153 
37,23 % 
375
31,89 %
Female 
385 
70,13 % 
158
73,15 %
258 
62,77 % 
801
68,11 %
Total 
549 
100,00 % 
216
100,00 %
411 
100,00 % 
1.176
100,00 %
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Table 1 : Age Distribution 
 
Group Obs Mean Std. Err. Std. Dev. 95% Conf. Interval 
UNIBO 549 93,91075 ,1269501 2,974535 93,66138 94,16012
ISS 216 93,48148 ,1900817 2,793619 93,10682 93,85614
UNICAL 411 93,34793 ,1382179 2,80211 93,07623 93,61964
 
Of these subjects, 13 are part of the “never completed trios” group where it was not possible to 
recruit the second sibling because he/she died before the interview or changed his/her mind and 
refused to participate. Thus, in total 554 families of 2 or more siblings have been collected, 
consisting of 509 (91,88%) families of two siblings, 35 (6,32%) of three siblings, 9 (1,63%) of four 
and 1 (0,18%) of five siblings (Table 2). In the whole project only UNIBO, CRLC (France) and 
TAMPERE (Finland) managed to recruit families with five 90+ siblings. This result is noteworthy 
because it implies a greater effort in terms of economical and human resources to complete trios 
without neglecting any sibling in the families, allowing for insight on the human longevity in large 
families. 
 
Table 2: Family and number of members 
 
Members of the 
family 
Centre Total UNIBO ISS UNICAL 
2 215 102 192 509
3 24 4 7 35
4 8 0 1 9
5 1 0 0 1
Total 258 106 203 554
 
 
Remarkable is the fact that in our sample we collected 48 centenarians (100-105 y.o), of whom 1 
subject has reported a stroke episode in young age and 7 in old age (just one of these 90+ siblings 
was 102 y.o while the other six were 100 y.o. at the time of the interview). 
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Proxy interview 
In proxy interviews the items in the questionnaire are responded by the 90+ sib care giver, given 
that the 90+ sib is not able to participate actively to the study. Proxy interviews have been 
performed for the reason that in some families one of the siblings had poor cognitive and/or 
functional status, even if it’s sibling(s) were in a good status. 
Proxy interviews have been collected from 87 (25 male representing the 6,68% of the male 
population and 62 females, representing the 7,74% of the population) 90+ sibs, representing the 
7,40% of the whole sample. From these 51 proxy interview have been collected from UNIBO, 13 
from ISS and 23 from UNICAL, representing respectively the 9,29%, the 6,02% and the 9,29% of 
the total interviews collected from each centre 
Exists a statistically significant difference in the age between proxy interview and non-proxy 
interview. Proxy interview has been collected from older subjects (mean age 95.39 y.o.) confronting 
with the non-proxy interview subjects (mean age 93.49, p>0.00). 
 
In Table  is reported the distribution of proxy interviews according to the reported age of the first 
stroke event (cut-off = 85 y.o.). 60 proxy interviews are from free stroke subjects (5,14% of the 
total interviews), 5 are from the young age stroke group (0,43%) and 21 from the old age stroke 
group (1,8%). 
 
Table 3 : Distribution of proxy interviews according to the reported age of the first stroke event 
 
Proxy Interview Stroke Status and Age Onset Total Free 41-84 85-99 
Yes 60 5,14 % 
5
0,43 %
21 
1,80 % 
86
7,37 %
No 960 82,20 % 
42
3,60 %
80 
6,83 % 
1.082
92,63 %
Total 1.020 87,33 % 
47
4,02 %
101 
8,65 % 
1.168
100,00 %
 
 
In Table 3 we can see that 1 proxy interview (0,09% of the total) is from an ADL independent 90+ 
sib (ADL score 5-6), in 6 (0,51) proxy interviews 90+ sibs belong to ADL moderate dependent 
group (ADL score 3-4) and 80 (6,81%) to the ADL completely dependent group. 
Only 4 subjects of the proxy interviews were able to perform the chair standing test (0,34%) (Table 
5) and 29 (2,47%) were able to perform the hand grip test (Table 6). 
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Table 3 : Proxy interview and ADL score 
 
Proxy Interview ADL score Total 5 - 6 3 - 4 0 - 2 
Yes 1 0,09 % 
6
0,51 %
80 
6,80 % 
87
7,40 %
No 654 55,66 % 
117
9,96 %
317 
26,98 % 
1.088
92,60 %
Total 655 55,74 % 
123
10,47 %
397 
33,79 % 
1.175
100,00 %
 
 
Table 4 : Proxy interview and chair standing 
 
Proxy Interview? 
Chair Standing Performed 
Total 
Able Unable 
Yes 
4
0,34 %
83
7,07 %
87
7,41 %
No 
642
54,69 %
445
37,90 %
1.087
92,59 %
Total 
646
55,02 %
528
44,98 %
1.174
100,00 %
 
Table 5 : Proxy interview and hand grip 
 
Proxy Interview? Hand Grip Performed Total 
Yes No 
Yes 
29
2,47 %
58
4,93 %
87
7,40 %
No 
1.058
90,04 %
30
2,56 %
1.088
92,60 %
Total 
1.087
92,51 %
88
7,49 %
1.175
100,00 %
 
From this point data from proxy interview questionnaires (87 subjects) will not be considered for 
the analysis. We decide to not use these data, in order to avoid bias from the extreme disability 
(cognitive and functional deficit) that the proxy interview 90+ sib is affected. 
 
 48
 
Stroke Incidence 
We have divided our sample in three main categories according their answer in the 55c question 
(“Have you ever had one or more of the following diseases? Stroke, cerebral 
thrombosis/haemorrhage. If “yes”, report age of first time”). 
a) Stroke free: negative answer in the 55c question (960 subjects, 88.72%). 
b) Young age stroke: positive answer in the 55c question (42 subjects, 3.88%). Reported age of 
Stroke incidence < 85 y.o. 
c) Old age stroke: positive answer in the 55c question (80 subjects, 7.39%). Reported age of 
Stroke incidence ≥ 85y.o. 
 
Free stroke group is considered the reference category for all the following 
analysis. 
In Figure  we can see the distribution of the reported stroke incidence in different ages.  
It is remarkable the fact that incidence is low before 85 y.o and then increase sharply.  
 
Figure 1 : Distribution of stroke incidence in different ages 
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Regarding stroke incidence within the same family, our data report that in the 1.71% of the families 
composed of two 90+ siblings, both siblings have reported a stroke episode, while in 5.71% of the 
families composed by three 90+ siblings two siblings have reported a stroke episode (Table 6). 
However in this group as well as in the four 90+ siblings family, the small amount of families (just 
9 families are composed of four 90+ siblings and 35 of three 90+ siblings) does not allow any 
conclusion regarding the possible inheritance of the cerebrovascular disease within siblings. 
 
Table 6 : Incidence of stroke within the 90+ siblings family 
 
Members of the 
family 
Members affected by ictus Total 0 1 2 
2 388 76,23 % 
113
22,20 %
8 
1,57 % 
509
100,00 %
3 19 54,29 % 
14
40,00 %
2 
5,71 % 
35
100,00 %
4 5 55,56 % 
3
33,33 %
1 
11,11 % 
9
100,00 %
5 1 100,00 % 
0
0,00 %
0 
0,00 % 
1
100,00 %
Total 424 74,78 % 
132
23,28 %
11 
1,94 % 
567
100,00 %
 
 
In Table 7 is represented the statistical relationship between the presence or not and the age of 
reported stroke with:  
- Age at interview 
- sex  
- ability to understand the questions 
- can the participant walk 500 m without help 
- smoke habit 
- Alcohol daily consumption 
- Presence of serious memory impairments (e.g. dementia) 
- Daily Exercise or daily light housework 
- History of arthritis  
 
It is interesting that there is a correlation between stroke incidence age, walking without any help 
for 500 mt, the daily exercise and alcohol consumption. On the contrary and quite surprising, no 
correlation has been found between stroke status and sex of the participant, as well as with the 
smoke habit, even when we analysed the sample combining the categories of “actual” and “ex 
smoker”. 
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Table 7 : Stroke and variables 
 
Characteristics Stroke Status and Age Onset Total  Free* 41-84 85-99 
Subjects 960 42 80 1082 
Age at interview 
 mean st.dev mean st.dev mean st.dev mean st.dev p (ttest)
Years 93,46 2,83 92,83 2,50 94,26 2,68 93,49 2,81 0,08/0,99
Centre 
 n % n % n % n % p (chi2) 
UNIBO 426 44,4 24 57,2 44 55,0 494 45,7 
ISS 185 19,3 4 9,5 13 16,3 202 18,7 
RC 349 36,3 14 33,3 23 28,7 386 35,6 0,154
Sex  
 n % n % n % n % p (chi2) 
male 315 32,8 10 23,8 22 27,5 347 32,1 
female 645 67,2 32 76,2 58 72,5 735 67,9 0,313
Is the participant able to understand? 
 n % n % n % n % p (chi2) 
Yes 737 76,8 31 73,8 55 68,8 823 76,1 
Little or Great 
difficulties and No 
218 22,7 11 26,2 25 31,2 254 23,5 0,215
Can you WITHOUT difficulty walk  500 m WITHOUT help? 
 n % n % n % n % p (chi2) 
Yes 403 42,0 15 35,7 14 17,5 432 39,9 
No 557 58,0 27 64,3 66 82,5 650 60,1 <0,001
Smoke habit 
 n % n % n % n % p (chi2) 
Never 694 72,3 34 81,0 64 80,0 792 73,3 
Smoke History 
(Actual/Ex-Smoker) 
265 
(35/230) 
27,6 8
(0/8)
19,0 16
(2/14)
20,0 289 
(37/252) 
26,7 0,173
Daily Alcohol Consumption 
 n % n % n % n % p (chi2) 
Yes 523 54,5 21 50,0 40 50,0 624 57,7 
No 396 41,3 21 50,0 40 50,0 457 42,3 0,186
Presence of serious memory impairments (e.g. dementia) 
 n % n % n % n % p (chi2) 
No 895 93,2 38 90,5 71 88,8 1.004 92,8 
Yes 65 6,8 4 9,5 9 11,2 78 7,2 0,277
Daily light exercise 
 n % n % n % n % p (chi2) 
Yes 539 56,1 19 45,2 28 35,0 586 54,2 
No 421 43,9 23 54,8 52 65,0 496 45,8 <0,001
History of Arthritis 
 n % n % n % n % p (chi2) 
No 493 51,4 20 47,6 48 60,0 561 51,8 
Yes 467 48,6 22 52,4 32 40,0 521 48,2 0,283
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Afterwards the logistic regression test has been performed, to analyse the global effect of the 
variables in the 90+ siblings population. 
In the old age stroke group the age at interview, the inability to walk without any help and the 
absence of daily exercise represent risk factors for stroke incidence. (Table 8) 
 
Table 8 : Stroke and variables logistic regression 
 
Characteristics Stroke Status and Age Onset Free* vs 41-84 Free* vs 85-99 
 OR p lower upper OR p lower upper 
Age at interview 
years 0,91 0,155 0,81 1,03 1,10 0,006 1,03 1,17
centre 
UNIBO 1,00 reference category 
ISS 0,38 0,079 0,13 1,11 0,68 0,225 0,37 1,27
RC 0,71 0,322 0,36 1,39 0,64 0,103 0,37 1,10
sex 
male 1,00 reference category 
female 1,56 0,227 0,76 3,23 1,29 0,327 0,78 2,14
Is the participant able to understand? 
Yes 1,00 reference category 
Little or Great difficulties 
and No 
1,20 0,614 0,59 2,43 1,54 0,084 0,94 2,50
Can you WITHOUT difficulty walk 500 m WITHOUT help? 
Yes 1,00 reference category 
No 1,30 0,408 0,70 2,43 3,41 0,000 1,91 6,09
Smoke habit 
Never 1,00 reference category 
Act/Ex-Smoker 0,62 0,229 0,28 1,36 0,65 0,145 0,37 1,16
Daily Alcohol Consumption 
Yes 1,00 reference category 
No 1,42 0,249 0,78 2,59 1,42 0,119 0,91 2,12
Serious memory impairments (e.g. dementia) 
No 1,00 reference category 
Yes 1,45 0,489 0,51 4,15 1,75 0,134 0,84 3,62
Daily light exercise 
Yes 1,00 reference category 
No 1,55 0,170 0,83 2,90 2,38 0,000 1,47 3,86
History of Arthritis 
No 1,00 reference category 
Yes 1,16 0,623 0,64 2,11 0,70 0,136 0,44 1,12
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Cognitive status 
The SMMSE was used as measure of the cognitive status of 90+ siblings and it was calculated in a 
total of 1084 subjects. Four (n.4) subjects have not complete the SMMSE because of physical 
disability (i.e. Visually impaired, Hearing impaired, Paralyzed in the arms, etc). 
The raw SMMSE score was adjusted for age and years of education according to the reference 
given by Magni et al. 1996 in a study on Italian population and our sample has been classified in 
two groups:  
iii) Normal cognitive status (MMSE ≥24): 446 of 90+ sibs (41.37%) 
iv) Cognitive Impairment (MMSE < 24): 637 of 90+ sibs (58.76%) 
Since the 58.76% of our sample was cognitively impaired, a further analysis of this group has been 
performed, dividing the subjects in those with MMSE score between 20 - 24, 15 - 19 and ≤ 14, 
according to the Scott et al classification, and the presence and age of stroke incidence. (Table 9)  
 
Table 9 : MMSE score and stroke incidence 
 
MMSE Score Ictus free 41-84 85-99 Total 
≤ 14 
Severe Cognitive Impairment 
152
15,90 %
9 
21,43 % 
19 
23,75 % 
180
16,70 %
15-19 
Moderate Cognitive Impairment 
215
22,49 %
8 
19,05 % 
18 
22,50 % 
241
22,36 %
20-24 
Mild Cognitive Impairment 
182
19,04 %
13 
30,95 % 
16 
20,00 % 
211
19,57 %
≥24 
Normal Cognitive Status 
407
42,57 %
12 
28,57 % 
27 
33,75 % 
446
41,37 %
 
As we can see almost 42% of our population belongs to the mild and moderate cognitive 
impairment groups, and just the 16.7% of the sample is affected by a severe cognitive impairments. 
This correspond to the GeHA spirit, according to which 90+ relatively healthy subjects were 
supposed to participate to the project. 
 
In Figure 1 is represented the MMSE score distribution, adjusted for educational level. 
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Figure 1 : MMSE score distribution, adjusted for educational level 
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In Table 10 we can see that MMSE score adjusted for educational level is strongly correlated with 
the majority of the variables considered to perform this analysis: interview age of the participant, 
sex of the participant, ability to understand the questions, can the participant walk without help, 
smoke habit, Alcohol daily consumption, Presence of serious memory impairments (e.g. dementia), 
Daily Exercise or daily light housework, at the exception of History of Arthritis. 
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Table 10 : MMSE score adjusted for educational level and variables 
Characteristics 
MMSE Adjusted for Educational Level 
mmse>=24 mmse<24 totale  
Subject 447 637 1084  
Stroke Status and Age Onset 
 n % n % n % p (chi2) 
Free* 407 91,1 549 86,2 956 88,2 0,07 
41-84 12 2,7 30 4,7 42 3,9  
85-99 27 6,0 53 8,3 80 7,4  
Age at interview 
 mean st.dev mean st.dev mean st.dev p (ttest) 
years 92,9 2,43 93,9 2,95 93,5 2,80 <0.001 
Centre 
 n % n % n % p (chi2) 
UNIBO 259 57,9 236 37,0 495 45,7  
ISS 133 29,8 69 10,8 202 18,6  
RC 55 12,3 332 52,1 387 35,7 <0,001 
Sex 
 n % n % n % p (chi2) 
male 165 36,9 182 28,6 347 32,0  
female 282 63,1 455 71,4 737 68,0 0,004 
Is the participant able to understand 
 n % n % n % p (chi2) 
Yes 417 93,3 409 64,2 826 76,2  
Little or Great difficulties and No 27 6,0 226 35,5 253 23,3 <0,001 
Can you WITHOUT difficulty walk 500 m WITHOUT help? 
 n % n % n % p (chi2) 
Yes 227 50,8 207 32,5 434 40,0  
No 220 49,2 430 67,5 650 60,0 <0,001 
Smoke habit 
 n % n % n % p (chi2) 
Never 296 66,2 495 77,7 791 73,0  
Act/Ex-Smoker 151 33,8 140 22,0 291 26,8 <0,001 
Daily Alcohol Consumption 
 n % n % n % p (chi2) 
Yes 280 62,6 346 54,3 626 57,7  
No 166 37,1 291 45,7 457 42,2 <0,001 
Serious memory impairments (e.g. dementia) 
 n % n % n % p (chi2) 
No 442 98,9 564 88,5 1006 92,8  
Yes 5 1,1 72 11,3 77 7,1 <0,001 
Daily Alcohol Consumption 
 n % n % n % p (chi2) 
Yes 338 75,6 249 39,1 587 54,2  
No 109 24,4 388 60,9 497 45,8 <0,001 
History of Arthritis 
 n % n % n % p (chi2) 
No 251 56,2 309 48,5 560 51,7  
Yes 196 43,8 327 51,3 523 48,2 0,014 
 55
Performing the logistic regression test we have obtain some interesting results: 
There is a major risk to have a cognitive impairment (MMSE < 24) if the 90+ sib belongs to the 
Young age stroke, if she is a female, leaves in Calabria, drinks moderate quantity of alcohol, 
doesn’t perform any kind of light exercise and is affected by arthritis. 
Unexpectedly, smoke habit results a slight protective factor! (OR 0.55, p<0.001). 
These results are reported in Table 11 
 
Table 11 : MMSE score and variables Logistic regression 
Characteristics MMSE Adjusted for Educational Level 
 mmse<24 vs mmse>=24 
 OR p lower upper 
Stroke Status and Age Onset 
free * reference category 
41-84 1,85 0,077 0,94 3,67
85-99 1,46 0,124 0,90 2,35
Age at interview 
years 1,16 <0,001 1,10 1,22
Centre 
UNIBO reference category 
ISS 0,57 0,004 0,39 0,84
RC 6,62 <0,001 4,60 9,55
Sex 
male reference category 
female 1,46 0,004 1,13 1,89
Is the participant able to understand? 
Yes reference category 
Little or Great difficulties and No 8,53 <0,001 5,61 12,99
Can you WITHOUT difficulty walk 500 m WITHOUT help? 
Yes reference category 
No 2,14 <0,001 1,66 2,76
Smoke habit 
Never reference category 
Act/Ex-Smoker 0,55 <0,001 0,42 0,72
Daily Alcohol Consumption 
Yes reference category 
No 1,42 0,007 1,10 1,83
Serious memory impairments (e.g. dementia) 
No reference category 
Yes 11,29 <0,001 4,56 27,92
Daily light exercise 
Yes reference category 
No 4,83 <0,001 3,64 6,42
History of Arthritis 
No reference category 
Yes 1,36 0,024 1,04 1,76
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Presence of daily disability 
Using the ADL scale we have divided our sample in: 
- ADL independent (ADL score 5-6). In this category belongs the 60.11% of our 
sample (654 90+ sibs). These subjects have been interviewed in relatively younger 
age comparing with the other two categories (Mean age at interview 92,95 y.o.) 
- ADL moderate dependent (ADL score 3-4). In this category belongs the 10.75% 
of our sample (117 90+sibs, Mean age at interview 94,15 y.o.) 
- ADL completely dependent (ADL score 0-3). In this category belongs the 29.14% 
of our sample (317 90+sibs, Mean age at interview 94,59.o.)  
 
In Figure 2 is represented the ADL score distribution 
 
Figure 2 : ADL score distribution 
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ADL score resulted statistically associated with all the different variables, as reported in Table 12. 
Table 12 : ADL score and variables 
Characteristics ADL Status  
 5-6 3-4 0-2 Totale  
Subject 654 117 317 1088  
Stroke Status and Age Onset 
 n % n % n % n % p (chi2) 
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Performing the logistic regression test the results are analogous as the ones we have seen for the 
MMSE score. Once more there is a major risk to be completely dependent in the ADL if the 90+ 
subjects is a female, leaving in Calabria, drinks moderate quantity of alcohol, doesn’t perform any 
kind of light exercise and is affected by arthritis. In addition smoke habit is a risk factor for low 
ADL scores. 
free* 601 91,9 103 88,0 256 80,8 960 88,2  
41-84 17 2,6 7 6,0 18 5,7 42 3,9  
85-99 32 4,9 7 6,0 41 12,9 80 7,4 <0,001 
Age at interview 
 mean st.dev mean st.dev mean st.dev mean st.dev p (ttest) 
years 92,95 2,48 94,15 2,94 94,59 3,19 93,90 2,69  
Centre 
 n % n % n % n % p (chi2) 
UNIBO 307 46,9 70 59,8 121 38,2 498 45,8  
ISS 134 20,5 29 24,8 40 12,6 203 18,7  
RC 213 32,6 18 15,4 156 49,2 387 35,6 <0,001 
sex 
 n % n % n % n % p (chi2) 
male 245 37,5 32 27,4 72 22,7 349 32,1  
female 409 62,5 85 72,6 245 77,3 739 67,9 <0,001 
Is the participant able to understand 
 n % n % n % n % p (chi2) 
Yes 574 87,8 73 62,4 180 56,8 827 76,0  
Little or Great 
difficulties and No 
79 12,1 41 35,0 136 42,9 256 23,5 <0,001 
Can you WITHOUT difficulty walk 500 m WITHOUT any help? 
 n % n % n % n % p (chi2) 
Yes 382 58,4 29 24,8 24 7,6 435 40,0  
No 272 41,6 88 75,2 293 92,4 653 60,0 <0,001 
Smoke habit 
 n % n % n % n % p (chi2) 
Never 445 68,0 85 72,6 264 83,3 794 73,0  
Ex-Smoker+Actual 208 31,8 32 27,4 52 16,4 292 26,8 <0,001 
Daily Alcohol Consumption 
 n % n % n % n % p (chi2) 
Yes 408 62,4 64 54,7 157 49,5 629 57,8  
No 245 37,5 53 45,3 160 50,5 458 42,2 <0,001 
Serious memory impairments (e.g. dementia) 
 n % n % n % n % p (chi2) 
No 635 97,1 103 88,0 271 75,7 1009 92,7  
Yes 18 2,9 14 12,0 46 23,8 78 7,2 <0,001 
Daily light exercise 
 n % n % n % n % p (chi2) 
Yes 510 78,0 54 46,2 25 7,9 589 54,1  
No 144 22,0 63 53,8 292 92,1 499 45,9 <0,001 
History of Arthritis 
 n % n % n % n % p (chi2) 
No 355 54,3 66 56,4 142 44,8 563 51,7  
Yes 298 45,6 51 43,6 175 55,2 524 48,2 0,011 
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Table 13 : ADL score and variables, Logistic regression 
 
Characteristics 
ADL Status 
3-4 vs 5-6 0-2 vs 5-6 
 OR p lower upper OR p lower upper 
Stroke Status and Age Onset 
Free* reference category reference category 
41-84 2,40 0,061 0,96 6,00 2,49 0,006 1,30 4,78
85-99 1,28 0,574 0,55 2,99 3,00 0,000 1,85 4,88
Age at interview 
years 1,17 0,000 1,10 1,25 1,20 0,000 1,14 1,27
centre 
UNIBO reference category reference category 
ISS 0,95 0,848 0,56 1,62 0,76 0,235 0,48 1,20
RC 0,37 0,000 0,22 0,64 1,86 0,002 1,36 2,55
sex 
male reference category reference category 
female 1,59 0,035 1,03 2,45 2,04 0,000 1,50 2,77
Is the participant able to understand 
Yes reference category reference category 
Little or Great difficulties and 
No 
4,08 0,000 2,53 6,58 5,49 0,000 3,96 7,61
Can you WITHOUT difficulty walk 500 m WITHOUT any help? 
Yes reference category reference category 
No 17,15 0,000 10,81 27,20 4,26 0,000 2,76 6,59
Smoke habit 
Never reference category reference category 
Act/Ex-Smoker 0,81 0,336 0,52 1,25 0,42 0,000 0,30 0,59
Daily Alcohol Consumption 
Yes reference category reference category 
No 1,38 0,101 0,94 2,02 1,70 0,000 1,30 2,22
Serious memory impairments (e.g. dementia) 
No reference category reference category 
Yes 4,80 0,000 2,26 10,17 5,99 0,000 3,35 10,70
Daily light exercise 
Yes reference category reference category 
No 4,13 0,000 2,72 6,28 41,37 0,000 26,36 64,92
History of Arthritis 
No reference category reference category 
Yes 0,92 0,683 0,62 1,37 1,47 0,006 1,12 1,93
 
Functionality measures 
Two functionality test have been carried out: The chair standing test that provides information about 
the lower limbs functionality and the hand grip test for the upper limbs. 
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A. CHAIR STANDING. 
In our population the 59.06% of the 90+ subject were able to perform the chair standing test, the 
6.53% had to stop after one to four attempts and the 34.41% were unable to complete the test. 
Therefore the 40.94% were incapable to accomplish test. These 90+ sibs are older (mean age 94.30 
y.o., p<0,001) than the ones that were able to perform the chair standing test (mean age 92.93 y.o.). 
 
More over the capacity to carry out the chair test is strongly correlated with the majority of the 
variables except, alcohol consumption and presence of arthritis. Slight correlation exists also with 
smoke. (Table 14) 
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Table 14 : Chair Standing test correlation with variables 
 
Characteristics Perform Chair Standig  
Able Unable Totale 
Subject 642 445 1087  
Stroke Status and Age Onset 
 n % n % n % p (chi2) 
free 593 92,4 366 82,2 959 88,2  
41-84 17 2,6 25 5,6 42 3,9  
85-99 30 4,7 50 11,2 80 7,4 <0,001 
Age at interview 
 mean st.dev mean st.dev mean st.dev p (ttest) 
years 92,93 2,51 94,30 3,02 93,50 2,81 <0,001 
     
centre 
 n % n % n % p (chi2) 
UNIBO 239 37,2 259 58,2 498 45,8  
ISS 90 14,0 113 25,4 203 18,7  
RC 313 48,8 73 16,4 386 35,5 <0,001 
sex 
 n % n % n % p (chi2) 
male 238 37,1 110 24,7 348 32,0  
female 404 62,9 335 75,3 739 68,0 <0,001 
Is the participant able to understand 
 n % n % n % p (chi2) 
Yes 550 85,7 276 62,0 826 76,0  
Little or Great difficulties and No 90 14 165 37,1 256 23,6 <0,001 
Can you WITHOUT difficulty walk 500 m WITHOUT any help? 
 n % n % n % p (chi2) 
Yes 376 58,6 58 13,0 434 39,9  
No 266 41,4 387 87,0 653 60,1 <0,001 
Smoke habit 
 n % n % n % p (chi2) 
Never 455 70,9 339 76,2 794 73,0  
Ex-Smoker+Actual 186 28,9 105 23,6 291 26,8 0,05 
Daily Alcohol Consumption 
 n % n % n % p (chi2) 
Yes 383 59,7 245 55,1 628 57,8  
No 258 40,2 200 44,9 458 42,1 0,123 
Serious memory impairments (e.g. dementia) 
 n % n % n % p (chi2) 
No 619 96,4 389 87,4 1008 92,7  
Yes 23 3,6 55 12,4 78 7,2 <0,001 
Daily light exercise 
 n % n % n % p (chi2) 
Yes 440 68,5 148 33,3 588 54,1  
No 202 31,5 297 66,7 499 45,9 <0,001 
History of Arthritis 
 n % n % n % p (chi2) 
No 339 52,8 223 50,1 562 51,7  
Yes 303 47,2 222 49,1 524 48,2 0,403 
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Performing the logistic regression test we notice that the reported age of first stroke episode, age at 
interview, female sex, presence of cognitive impairment and functional inability represent risk 
factors for the capacity to perform the chair standing test. 
No statistically significant correlation have been found with the chair test performance and alcohol 
consumption, history of arthritis or smoke habit. (Table 15) 
 
Table 15 : Chair Standing test and variables: Logistic regression 
 
Characteristics 
Perform Chair Standig 
Unable vs Able 
 OR p lower upper 
Stroke Status and Age Onset 
free reference category 
41-84 2,38 0,005 1,30 4,38
85-99* 2,70 0,000 0,70 4,28
Age at interview 
years 1,20 0,000 1,14 1,26
centre 
UNIBO reference category 
ISS 1,16 0,428 0,81 1,67
RC 0,22 0,000 0,16 0,30
sex 
male reference category 
female 1,79 0,000 1,37 2,34
Is the participant able to understand 
Yes reference category 
Little or Great difficulties and No 3,61 0,000 2,68 4,87
Can you WITHOUT difficulty walk 500 m WITHOUT any help? 
Yes reference category 
No 9,43 0,000 6,77 13,14
Smoke habit 
Never reference category 
Act/Ex-Smoker 0,76 0,056 0,57 1,01
Daily Alcohol Consumption 
Yes reference category 
No 1,21 0,124 0,95 1,55
Serious memory impairments (e.g. dementia) 
No reference category 
Yes 3,81 0,000 2,24 6,45
Daily light exercise 
Yes reference category 
No 4,37 0,000 3,38 5,65
History of Arthritis 
No reference category 
Yes 1,11  0,42 0,86 1,42
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B HAND GRIP TEST. 
From our sample the 97,33% of the 90+ subject was able to perform the hand grip test, while the 
2,67% was unable to complete or perform the test. These 90+ sibs are older (mean age 95,03 y.o., 
p=0,0014) than the ones that were able to perform the chair standing test (mean age 93,45 y.o.). 
 
Table 16 reports the descriptive analysis for the hand grip test. 
More over the capacity to carry out the chair test is strongly correlated with the majority of the 
variables except, alcohol consumption and smoke habit.  
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Table 16 : Hand grip test and vorrelation with variables 
 
Characteristics Perform Hand Grip Test  
No Yes Total 
Subject 29 1059 1088  
Stroke Status and Age Onset 
 n % n % n % p (chi2) 
free* 21 72,4 939 88,7 960 88,2  
41-84 2 6,9 40 3,8 42 3,9  
85-99 4 13,8 76 7,2 80 7,4 <0,001 
Age at interview 
 mean st.dev mean st.dev mean st.dev p (ttest) 
years 95,03 3,10 93,45 2,79 93,49 2,81 0,0014 
centre 
 n % n % n % p (chi2) 
UNIBO 20 69,0 478 45,1 498 45,8  
ISS 5 17,2 198 18,7 203 18,7  
RC 4 13,8 383 36,2 387 35,5 0,023 
sex 
 n % n % n % p (chi2) 
male 2 6,9 347 32,8 349 32,1  
female 27 93,1 712 67,8 739 67,9 0,003 
Is the participant able to understand 
 n % n % n % p (chi2) 
Yes 9 31,0 818 77,2 827 76,0  
Little or Great difficulties and No 20 69,0 236 22,3 256 23,5 <0,001 
Can you WITHOUT difficulty walk 500 m WITHOUT any help? 
 n % n % n % p (chi2) 
Yes 2 6,9 433 40,9 435 40,0  
No 27 93,1 626 59,1 653 60,0 <0,001 
Smoke habit 
 n % n % n % p (chi2) 
Never 25 86,2 769 72,6 794 73,0  
Ex-Smoker+Actual 3 10,3 289 27,3 292 26,8 0,051 
Daily Alcohol Consumption 
 n % n % n % p (chi2) 
Yes 12 41,4 617 58,3 629 57,8  
No 17 58,6 441 41,6 458 42,1 0,068 
Serious memory impairments (e.g. dementia) 
 n % n % n % p (chi2) 
No 20 69,0 989 93,4 1009 92,7  
Yes 8 27,6 70 6,6 78 7,2 <0,001 
Daily light exercise 
 n % n % n % p (chi2) 
Yes 4 13,8 585 55,2 589 54,1  
No 25 86,2 474 44,8 499 45,9 <0,001 
History of Arthritis 
 n % n % n % p (chi2) 
No 5 17,2 558 52,7 563 51,7  
Yes 23 79,3 501 47,3 524 48,2 <0,001 
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Performing the logistic regression test we notice that the age at interview, female sex, presence of 
cognitive impairment and functional inability and history of arthritis represent risk factors for the 
capacity to perform the chair standing test. 
Unexpectedly no statistically significant correlation has been found with the first stroke event 
reported age.  
Again, no correlation resulted with smoke habit and alcohol consumption. (Table 17) 
 
Table 17 : Hand grip and variables logistic regression test 
 
Characteristics 
Perform Hand Grip Test 
No vs Yes 
 OR p lower upper 
Stroke Status and Age Onset 
free * reference category 
41-84 2,24 0,291 0,50 9,96
85-99 2,35 0,131 0,77 7,14
Age at interview 
years 1,18 0,002 1,06 1,31
centre 
UNIBO reference category 
ISS 0,60 0,105 0,23 1,162
RC 0,25 0,012 0,08 0,74
sex 
male reference category 
female 6,58 0,011 1,54 28,06
Is the participant able to understand? 
Yes reference category 
Little or Great difficulties and No 7,07 0,000 3,41 17,40
Can you WITHOUT difficulty walk 500 m WITHOUT any help? 
Yes reference category 
No 9,34 0,003 2,19 39,76
Smoke habit 
Never reference category 
Act/Ex-Smoker 0,32 0,065 0,95 1,07
Daily Alcohol Consumption 
Yes reference category 
No 1,98 0,080 0,92 4,26
Serious memory impairments (e.g. dementia) 
No reference category 
Yes 5,65 0,000 2,38 13,40
Daily light exercise 
Yes reference category 
No 7,71 0,000 2,65 22,43
History of Arthritis 
No reference category 
Yes 5,12 0,001 1,93 13,62
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MULTIVARIATE ANALYSIS 
When the multivariate analysis is performed in the total of the variables and the tests that we 
consider to describe the cognitive and functional status of the 90+ sibs some we obtain some very 
interesting results. 
In figure 4, we can notice that in all the tests the old age stroke group Odds ratio are lower than the 
young age stroke group. 
This result is very important since we can assume that young age stroke subjects are functionally 
and cognitively in a worst status comparing with the old age stroke! 
Figure 4: Stroke groups versus stroke free odds ratio 
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Table 18 reports the summary of the values of the multivariate analysis. 
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Table 18 : Multivariate analysis, summary 
 
Characteristics Stroke Status and Age Onset Crude Adjusted** 
Free* 41-84 85-99 41-84 85-99 41-84 85-99 
 N N N OddsRatio OddsRatio OddsRatio OddsRatio
 (%) (%) (%) (95%CI) (95%CI) (95%CI) (95%CI) 
MMSE Adjusted for Educational Level 
mmse>=24* 
407 12 27 Reference Category Reference Category 
(42,57) (28,57) (33,75) Reference Category Reference Category 
mmse<24 
549 30 53 1,9 1,5 2,4 1,4 
(57,43) (71,43) (66,25) (0,99-4,53) (0,59-2,49) (1,02-5,46) (0,69-2,83)
ADL Status 
5 - 6* 
601 17 32 Reference Category Reference Category 
(62,6) (40,48) (40) Reference Category Reference Category 
3 - 4 
103 7 7 2,4 1,3 2,9 0,7 
(10,73) (16,67) (8,75) (0,96-6,01) (0,55-2,99) (0,95-8,6) (0,28-2,04)
0 - 2 
256 18 41 2,5 3,0 3,4 1,8 
(26,67) (42,86) (51,25) (1,29-4,78) (1,85-4,88) (1,12-10,2) (0,82-3,99)
Perform Chair Standig 
Able* 
593 17 30 Reference Category Reference Category 
(61,84) (40,48) (37,5) Reference Category Reference Category 
Unable 
366 25 50 2,4 2,7 3,2 1,4 
(38,16) (59,52) (62,5) (1,30-4,38) (1,70-4,28) (1,57-6,55) (0,78-2,53)
Perform Hand Grip Test 
No* 
21 2 4 Reference Category Reference Category 
(2,19) (4,76) (5) Reference Category Reference Category 
Yes 939 40 76 2,2 2,4 2,1 1,8 (97,81) (95,24) (95) (0,50-9,96) (0,78-7,14) (0,48-9,53) (0,5-6,62) 
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MORTALITY AND STROKE 
The vital status of GEHA 90+ siblings was checked at January 1st, 2009 and the results of the 
mortality analysis, as reported in Table 19, indicate that 538 out of 1081 subjects died (49,77%) 
during the follow-up . Mortality was higher in the old age stroke group (65%, p < 0,05) while was 
similar in the stroke free (48,59%) and young age stroke group (47,62%). p values were calculated 
according to Cox regression-based test for equality of survival curves.  
 
Table 19 : Survival and stroke in January 1st 2009 
 
Status Stroke Status and Age Onset Total Free 41-84 85-99 
Not Alive 466 48,59 % 
20
47,62 %
52 
65,00 % 
538
49,77 %
Alive 493 51,41 % 
22
52,38 %
28 
35,00 % 
543
50,23 %
Total 959 100,00 % 
42
100,00 %
80 
100,00 % 
1.081
100,00 %
Pearson chi2(2) =   8,0325   Pr = 0,018 Pr = 0,018 
 
In Figure 5 we can see that stroke affected group survive less in comparison with the stroke free 
group. The survival curves are almost parallel from 1 year until near the 3 and a half years after the 
interview. Following the 3 and a half years, survival curve of the stroke affected group becomes 
more abrupt. 
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Figure 5: Stroke free and stroke affected subjects survival curves  
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In Figure 6 we can see the differences in the survival curves between the stroke free group, the old 
age stroke and the young age stroke groups. 
We can notice that survival curves of the old age stroke and the stroke free group almost overlap in 
the first half year and then the old age stroke group has a sharper form. 
Curiously the young age stroke group survival curve follows the old age stroke group until the year 
and a half from the interview and then follows the stroke free group survival curve. 
 
Figure 6: Stroke free, old and young age stroke group survival curves  
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Finally, the Cox regression-based test for equality of survival curves has been performed 
subdividing our population in 4 categories according to the presence or not of the following 
variables: MMSE score ≥ 24, ADL score 5-6, Chair standing test performed. 
We considered these variables to investigate the presence and degree of disability/frailty and it’s 
influence to the survival. 
Fom this analysis we have not use the hand grip data, since just 29 subjects could not complete the 
test. 
 70
 
Category 0: All the variables are present (excellent performance group) 
Category 1: One of the variables is lacking  
Category 2: Two of the variables are lacking 
Category 3: All the variables are lacking (worst performance group) 
 
In Table 22 and 23 are reported the distribution of not alive and alive subjects subdivided  by the 
four categories and the distribution of the four categories within the stroke age and stroke free 
groups, respectably.  
 
Table 22. Alive and not alive subjects in the 4 categories 
 
Status somm3 Total 0 1 2 3 
Not Alive 133 74,30 % 
144
59,26 %
176
46,32 %
88 
30,88 % 
541
49,77 %
Alive 46 25,70 % 
99
40,74 %
204
53,68 %
197 
69,12 % 
546
50,23 %
Total 179 100,00 % 
243
100,00 %
380
100,00 %
285 
100,00 % 
1.087
100,00 %
Pearson chi2(3) =  94,3481 Pr = 0,000 
 
 
Table23. Stroke status and 4 categories 
 
 
somm3 Status and Age Onset Total Free 41-84 85-99 
0 137 14,27 % 
15
35,71 %
25 
31,25 % 
177
16,36 %
1 208 21,67 % 
7
16,67 %
27 
33,75 % 
242
22,37 %
2 349 36,35 % 
14
33,33 %
15 
18,75 % 
378
34,94 %
3 266 27,71 % 
6
14,29 %
13 
16,25 % 
285
26,34 %
Total 960 100,00 % 
42
100,00 %
80 
100,00 % 
1.082
100,00 %
Pearson chi2(6) =  41,1510 Pr = 0,000   
 
In 7 we can see the survival curves of the four categories. As expected the subjctes of category 0 
survive more than the other groups. Worst survivals are the Category 4 subjects (more fragile). 
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Figure 7 : Survival curves of the four categories 
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DISCUSSION 
 
Stroke represents the 3rd cause of deaths for the industrialized countries, and the most important 
factor of invalidity. One of the non modifiable risk factors of stroke is the age.  
On the other hand, exists a well documented change on the life expectancy, with the important 
increase of the old and very old subjects. 
During the last years of the PhD course, I had the opportunity to work in an Intensive Rehabilitation 
Unit specialized on Neurological Disease, where the majority of the patients was affected by 
ischemic or hemorrhagic stroke, as a Clinician specialized in Geriatric Medicine. I had the chance 
to follow a various number of stroke affected patients from their admission (a week after the acute 
stroke episode until) until their discharge (60 days later). During this period patients are treated for 
their disability according to a specific intense motor and (when necessary) neuropsychological 
treatment, consisting of 2 hours/day of motor rehabilitation and 1 hour/day of neuropsychological 
treatment. 
With my Colleagues we notice that geriatric patients were less disable in admission and they 
recovered better than the younger patients. In fact, when we analysed the outcomes after specific 
rehabilitation treatment of Unilateral spatial neglect (USN) (a neuropsychological disorder 
whereby patients fail to detect objects, or execute movements in the portion of space controlateral to 
the side of brain lesion) we notice that aged patients (>80 y.o) had best performance in admission 
and high percentages of recovery, on cognitive status. (Data presented as Poster presentation in the 
IAAG World Congress, Paris 2009). 
Comparing with the motor recovery and increasing the sample, we obtain similar results (data 
submitted in the IAAG European Congress, Bologna April 2011). (Figure A) 
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Figure A. Outcomes after intensive rehabilitation in USN affected patients 
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At this point we thought that it would be interesting to see in the GeHA subjects if the age incidence 
of stroke is lower than the general population, classify them according to their functional and 
cognitive status and compare the stroke GeHA subjects mortality rates with the stroke free GeHA 
subjects. 
Our analysis have shown that just the 3,88% of the population belongs to the young age stroke, 
which could be explained from the fact that individuals with less than 85 y.o. affected by stroke 
have higher mortality rates than the general population. There for, these subjects are to be 
considered “survivors”. The prevalence of stroke in the old age stroke is 7,9%, slightly higher than 
the one in the Italian population (6,5%, (88)), probably due to the very old age. 
Regarding stroke incidence within the same family, our data report that in the 1.71% of the families 
composed of two 90+ siblings, both siblings have reported a stroke episode, while in 5.71% of the 
families composed by three 90+ siblings two siblings have reported a stroke episode (Table 6). 
However in this group as well as in the four 90+ siblings family, the small amount of families (just 
9 families are composed of four 90+ siblings and 35 of three 90+ siblings) does not allow any 
conclusion regarding the possible inheritance of the cerebrovascular disease within siblings. 
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As expected GeHA stroke affected subjects resulted disable to walk or to perform a light daily 
exercise. Quite surprising, no correlation has been found between stroke status and sex of the 
participant, as well as with the smoke habit, even when we analysed the sample combining the 
categories of “actual” and “ex smoker”.  
Regarding the Cognitive performance, there is a major risk to have a cognitive impairment (MMSE 
< 24) if the 90+ sib belongs to the Young age stroke, if she is a female, leaves in Calabria, drinks 
moderate quantity of alcohol, doesn’t perform any kind of light exercise and is affected by arthritis. 
Performing the logistic regression test the results regarding the ADL score are analogous as the 
ones we have seen for the MMSE score. Once more there is a major risk to be completely 
dependent in the ADL if the 90+ subjects is a female, leaving in Calabria, drinks moderate quantity 
of alcohol, doesn’t perform any kind of light exercise and is affected by arthritis.  
Regarding chair standing test we notice that the reported age of first stroke episode, age at 
interview, female sex, presence of cognitive impairment and functional inability represent risk 
factors for the capacity to perform the chair standing test. 
More over the capacity to carry out the chair test is strongly correlated with the majority of the 
variables except, alcohol consumption and smoke habit.  
It is of particular interest the fact that when we performed the multivariate analysis, old age stroke 
patients resulted to be in a better status both cognitive and functional, comparing to the young age 
stroke group!  
One of the hypothesis for the reason of this results could stand in the pathogenic moment of the 
acute stroke. Stroke determines a tissue necrosis, which activates the inflammatory factors. In 
young age the inflammatory respond is very strong, because is useful to survive infections. 
Probably in the old and very old subjects, the inflammatory respond is less important and 
consequently provoke a lighter cerebral tissue damage. This theory concords with the fact that 
inflammatory diseases can be a risk factor for stroke episode and an antinflammatory medicine is 
used worldwide to prevent stroke (acetylsalicylic acid). 
An other important finding of these analysis is the fact that even though old age stroke 90+ sibs 
resulted in a better condition, they leave less than the younger age stroke subjects. This could be for 
the following reasons: 
a) are older individuals and in this age frame one year of difference has an important weight in 
the mortality risk. 
b) Young age stroke group have been undergone at least for minimum four years in a 
secondary prevention treatment and have uphold life-style changes. In epidemiological 
studies there is a reduction on stroke re-incidence and a positive effect on the mortality after 
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life style changes and pharmacological treatment for hypertension, diabetes and 
hyperlipidemia (96, 97). So, these individuals have a worst outcome, but they survive more 
than the old age stroke group. 
 
 
 
 
CONCLUSIONS 
These data suggest that in the Italian GeHA population, a stroke episode in young age represents a 
risk factor for cognitive impairment, ADL disability and upper and/or lower limb disability, but 
secondary prevention is important to increase survival. 
Even though these findings are very interesting and confirms the fact that nonagenarians have 
singular performances, comparing to the younger ages, further studies (also within the GeHA 
project), should be conducted in order to validate these analysis. 
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